Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine – Science Advances

Abstract

Terminally differentiated murine osteocytes and adipocytes can be reprogrammed using platelet-derived growth factorAB and 5-azacytidine into multipotent stem cells with stromal cell characteristics. We have now optimized culture conditions to reprogram human adipocytes into induced multipotent stem (iMS) cells and characterized their molecular and functional properties. Although the basal transcriptomes of adipocyte-derived iMS cells and adipose tissuederived mesenchymal stem cells were similar, there were changes in histone modifications and CpG methylation at cis-regulatory regions consistent with an epigenetic landscape that was primed for tissue development and differentiation. In a non-specific tissue injury xenograft model, iMS cells contributed directly to muscle, bone, cartilage, and blood vessels, with no evidence of teratogenic potential. In a cardiotoxin muscle injury model, iMS cells contributed specifically to satellite cells and myofibers without ectopic tissue formation. Together, human adipocytederived iMS cells regenerate tissues in a context-dependent manner without ectopic or neoplastic growth.

The goal of regenerative medicine is to restore function by reconstituting dysfunctional tissues. Most tissues have a reservoir of tissue-resident stem cells with restricted cell fates suited to the regeneration of the tissue in which they reside (14). The innate regenerative capacity of a tissue is broadly related to the basal rate of tissue turnover, the health of resident stem cells, and the hostility of the local environment. Bone marrow transplants and tissue grafts are frequently used in clinical practice but for most tissues, harvesting and expanding stem and progenitor cells are currently not a viable option (5, 6). Given these constraints, research efforts have been focused on converting terminally differentiated cells into pluripotent or lineage-restricted stem cells (7, 8). However, tissues are often a complex mix of diverse cell types that are derived from distinct stem cells. Therefore, multipotent stem cells may have advantages over tissue-specific stem cells. To be of use in regenerative medicine, these cells would need to respond appropriately to regional cues and participate in context-dependent tissue regeneration without forming ectopic tissues or teratomas. Mesenchymal stem cells (MSCs) were thought to have some of these characteristics (911), but despite numerous ongoing clinical trials, evidence for their direct contribution to new tissue formation in humans is sparse, either due to the lack of sufficient means to trace cell fate in hosts in vivo or failure of these cells to regenerate tissues (12, 13).

We previously reported a method by which primary terminally differentiated somatic cells could be converted into multipotent stem cells, which we termed as induced multipotent stem (iMS) cells (14). These cells were generated by transiently culturing primary mouse osteocytes in medium supplemented with azacitidine (AZA; 2 days) and platelet-derived growth factorAB (PDGF-AB; 8 days). Although the precise mechanisms by which these agents promoted cell conversion was unclear, the net effect was reduced DNA methylation at the OCT4 promoter and reexpression of pluripotency factors (OCT4, KLF4, SOX2, c-MYC, SSEA-1, and NANOG) in 2 to 4% of treated osteocytes. iMS cells resembled MSCs with comparable morphology, cell surface phenotype, colony-forming unit fibroblast (CFU-F), long-term growth, clonogenicity, and multilineage in vitro differentiation potential. iMS cells also contributed directly to in vivo tissue regeneration and did so in a context-dependent manner without forming teratomas. In proof-of-principle experiments, we also showed that primary mouse and human adipocytes could be converted into long-term repopulating CFU-Fs by this method using a suitably modified protocol (14).

AZA, one of the agents used in this protocol, is a cytidine nucleoside analog and a DNA hypomethylating agent that is routinely used in clinical practice for patients with higher-risk myelodysplastic syndrome (MDS) and for elderly patients with acute myeloid leukemia (AML) who are intolerant to intensive chemotherapy (15, 16). AZA is incorporated primarily into RNA, disrupting transcription and protein synthesis. However, 10 to 35% of drug is incorporated into DNA resulting in the entrapment and depletion of DNA methyltransferases and suppression of DNA methylation (17). Although the relationship between DNA hypomethylation and therapeutic efficacy in MDS/AML is unclear, AZA is known to induce an interferon response and apoptosis in proliferating cells (1820). PDGF-AB, the other critical reprogramming agent, is one of five PDGF isoforms (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD), which bind to one of two PDGF receptors (PDGFR and PDGFR) (21). PDGF isoforms are potent mitogens for mesenchymal cells, and recombinant human (rh)PDGF-BB is used as an osteoinductive agent in the clinic (22). PDGF-AB binds preferentially to PDGFR and induces PDGFR- homodimers or PDGFR- heterodimers. These are activated by autophosphorylation to create docking sites for a variety of downstream signaling molecules (23). Although we have previously demonstrated induction of CFU-Fs from human adipocytes using PDGF-AB/AZA (14), the molecular changes, which underlie conversion, and the multilineage differentiation potential and in vivo regenerative capacity of the converted cells have not been determined.

Here, we report an optimized PDGF-AB/AZA treatment protocol that was used to convert primary human adipocytes, a tissue source that is easily accessible and requires minimal manipulation, from adult donors aged 27 to 66 years into iMS cells with long-term repopulating capacity and multilineage differentiation potential. We also report the molecular landscape of these human iMS cells along with that of MSCs derived from matched adipose tissues and the comparative in vivo regenerative and teratogenic potential of these cells in mouse xenograft models.

Primary mature human adipocytes were harvested from subcutaneous fat (Fig. 1A and table S1) and their purity confirmed by flow cytometry with specific attention to the absence of contaminating adipose-derived MSCs (AdMSCs) (fig. S1, A and B). As previously described (14), plastic adherent adipocytes were cultured in Alpha Minimum Essential Medium (MEM) containing rhPDGF-AB (200 ng/ml) and 20% autologous serum (AS) with and without 10 M AZA for 2 and 23 days, respectively (Fig. 1A). During daily observations, unilocular lipid globules were observed to fragment within adipocytes ~day 10 with progressive extrusion of fat into culture medium, coincident with changes in cell morphology (movie S1). Consistent with these observations, when fixed and stained with Oil Red O, adipocytes that were globular in shape at the start of culture resembled lipid laden stromal cells at day 12 and lipid-free stromal cells at day 25 (Fig. 1B).

(A) Generation and reprogramming of adipocytes. (B) Oil Red Ostained adipocytes (days 0, 12, and 25) during treatment with recombinant human platelet-derived growth factorAB (rhPDGF-AB) and AZA. (C) Flow cytometry plots of LipidTOX and PDGFR in adipocytes cultured as in (A). (D) CFU-F counts from treated and untreated adipocytes during conversion. (E) CFU-F counts from adipocytes treated (Rx) with indicated combinations of rhPDGF-AB, AZA, fetal calf serum (FCS), autologous serum (AS), or serum-free media (SFM). (F) CFU-F counts from adipocytes reprogrammed in the presence of 0, 1, or 10 M PDGFR/ inhibitor AG1296. (G) CFU-F counts per 400 reprogrammed adipocytes from three donor age groups (n = 3 for each) generated using indicated combinations of rhPDGF-AB and AZA. (H) Long-term growth of reprogrammed adipocytes from three donor age groups (n = 3 for each) generated using indicated combinations of rhPDGF-AB and AZA. (I) Long-term growth of iMS cells cultured in SFM or media supplemented with FCS, autologous, or allogeneic serum. Error bars indicate SD, n = 3; *P < 0.05, **P < 0.01, and ***P < 0.0001 calculated using either a Students t test (E and F) or a linear mixed model (H). Photo credit: Avani Yeola, UNSW Sydney.

To evaluate these changes in individual cells, we performed flow cytometry at multiple time points during treatment and probed for adipocyte (LipidTOX) (24) and stromal cell characteristics [PDGFR expression (25); Fig. 1C]. A subpopulation of adipocytes, when cultured in media supplemented with PDGF-AB/AZA and AS (Fig. 1C, top; treated), showed reduced LipidTOX staining intensity at day 10, with progressive reduction and complete absence in all cells by day 19. Adipocytes cultured in the absence of PDGF-AB/AZA retained LipidTOX staining, albeit with reduced intensity (Fig. 1C, bottom; untreated). Adipocytes expressed PDGFR [fig. S1C, (i) and (ii)] but not PDGFR (Fig. 1C) at day 0 but both the frequency and intensity of PDGFR staining increased from day 21. To record these changes in real time, we also continuously live-imaged treated adipocytes from days 15 to 25 and recorded the extrusion of fat globules, change in cell morphology from globular to stromal, and acquisition of cell motility and cell mitosis (movie S1 and fig. S1D). Intracellular fragmentation of fat globules was observed over time in untreated adipocytes (fig. S1E), consistent with variable LipidTOX staining intensity. CFU-F capacity was absent at day 10, present in day 15 cultures, and tripled by day 19 with no substantial increase at days 21, 23, and 25 (Fig. 1D). It is noteworthy that CFU-F potential was acquired before PDGFRA surface expression when adipocytes had started to display stromal cell morphology and had diminished fat content. There was also no CFU-F capacity in adipocytes cultured in MEM with fetal calf serum (FCS) or AS, unless supplemented with both PDGF-AB and AZA. CFU-F capacity was significantly higher with AS than with FCS and absent in serum-free media (SFM) (Fig. 1E and fig. S1F). As previously shown with reprogramming of murine osteocytes, there was dose-dependent inhibition of CFU-F capacity when AG1296, a potent nonselective PDGF receptor tyrosine kinase inhibitor (26), was added to the reprogramming media (Fig. 1F).

To evaluate the impact of patient age and concentrations of PDGF-AB and AZA on the efficiency of human adipocyte conversion, we harvested subcutaneous fat from donors aged 40 (n = 3), 41 to 60 (n = 3), and 61 (n = 3) years and subjected each to three different concentrations of PDGF-AB (100, 200, and 400 ng/ml) and three different concentrations of AZA (5, 10, and 20 M) (Fig. 1G). Although all combinations supported cell conversion in all donors across the three age groups, rhPDGF-AB (400 ng/ml) and 5 M AZA yielded the highest number of CFU-Fs (Fig. 1G). When these cultures were serially passaged in SFM (with no PDGF-AB/AZA supplementation, which was used for cell conversion only), adipocytes converted with reprogramming media containing rhPDGF-AB (400 ng/ml) and 5 M AZA were sustained the longest (Fig. 1H, fig. S2A, and table S2). The growth plateau that was observed even with these cultures [i.e., adipocytes converted with rhPDGF-AB (400 ng/ml) and 5 M AZA when expanded in SFM or FCS] was overcome when cells were expanded in either autologous or allogeneic human serum (Fig. 1I). The genetic stability of human iMS cells (RM0072 and RM0073) was also assessed using single-nucleotide polymorphism arrays and shown to have a normal copy number profile at a resolution of 250 kb (fig. S2B). Together, these data identify an optimized protocol for converting human primary adipocytes from donors across different age groups and show that these can be maintained long term in culture.

Given the stromal characteristics observed in human adipocytes treated with PDGF-AB/AZA (Fig. 1), we performed flow cytometry to evaluate their expression of MSC markers CD73, CD90, CD105, and STRO1 (13) and noted expression levels comparable to AdMSCs extracted from the same subcutaneous fat harvest (Fig. 2A). Primary untreated adipocytes (day 25 in culture) did not express any of these MSC markers (fig. S3A). The global transcriptomes of iMS cells and matched AdMSCs were distinct from untreated control adipocytes but were broadly related to each other [Fig. 2B, (i) and (ii)]. Ingenuity pathway analysis (IPA) using genes that were differentially expressed between AdMSCs versus adipocytes [3307 UP/4351 DOWN in AdMSCs versus adipocytes; false discovery rate (FDR) 0.05] and iMS versus adipocytes (3311 UP/4400 DOWN in iMS versus adipocytes; FDR 0.05) showed changes associated with gene expression, posttranslational modification, and cell survival pathways and organismal survival and systems development [Fig. 2B(iii)]. The number of differentially expressed genes between iMS cells and AdMSCs was limited (2 UP/26 DOWN in iMS versus AdMSCs; FDR 0.05) and too few for confident IPA annotation. All differentially expressed genes and IPA annotations are shown in table S3 (A to E, respectively).

(A) Flow cytometry for stromal markers on AdMSCs (green) and iMS cells (purple) from matched donors. Gray, unstained controls. (B) (i) Principal components analysis (PCA) plot of adipocyte, AdMSC, and iMS transcriptomes. (ii) Hierarchical clustering of differentially expressed genes (DEGs, FDR 0.05). (iii) Ingenuity pathway analysis (IPA) of DEG between AdMSCs/adipocytes (top) or iMS cells/adipocytes (bottom). The most enriched annotated biological functions are shown. (C) (i) Chromatin immunoprecipitation sequencing (ChIP-seq) profiles in AdMSCs and iMS cells from matched donors at a representative locus. Gray bar indicates differential enrichment. (ii) Volcano plots of H3K4me3, H3K27Ac, and H3K27me3 enrichment peaks significantly UP (red) or DOWN (blue) in iMS cells versus AdMSCs. (iii) IPA of corresponding genes. log2FC, log2 fold change. (D) (i) DNA methylation at a representative locus in AdMSCs and iMS cells from matched donors. (ii) Volcano plot of regions with significantly higher (red) or lower (blue) DNA methylation in iMS cells versus AdMSCs. (iii) IPA using genes corresponding to differentially methylated regions (DMRs). (E) OCT4, NANOG, and SOX2 expression in iPS, AdMSCs, and iMS cells. Percentage of cells expressing each protein is indicated. DAPI, 4,6-diamidino-2-phenylindole. (F) AdMSCs and iMS cells differentiated in vitro. Bar graphs quantify staining frequencies, error bars show SD, n = 3. ***P < 0.001 (Students t test). Photo credit: Avani Yeola, UNSW Sydney.

In the absence of significant basal differences in the transcriptomes of AdMSCs and iMS cells, and the use of a hypomethylating agent to induce adipocyte conversion into iMS cells, we examined global enrichment profiles of histone marks associated with transcriptionally active (H3K4me3 and H3K27Ac) and inactive (H3K27me3) chromatin. There were differences in enrichment of specific histone marks in matched AdMSCs versus iMS cells at gene promoters and distal regulatory regions [Fig. 2C(i) and fig. S3, B to D]. H3K4me3, H3K27ac, and H3K27me3 enrichments were significantly higher at 255, 107, and 549 regions and significantly lower at 222, 78, and 98 regions in iMS cells versus AdMSCs [Fig. 2C(ii) and table S4, A to C] and were assigned to 237, 84, and 350 and 191, 58, and 67 genes, respectively. IPA was performed using these gene lists to identify biological functions that may be primed in iMS cells relative to AdMSCs [Fig. 2C(iii) and table S4, D to F]. Among these biological functions, annotations for molecular and cellular function (cellular movement, development, growth, and proliferation) and systems development (general; embryonic and tissue development and specific; cardiovascular, skeletal and muscular, and hematological) featured strongly and overlapped across the different epigenetic marks.

We extended these analyses to also assess global CpG methylation in matched AdMSCs and iMS cells using reduced representation bisulfite sequencing [RRBS; (27)]. Again, there were loci with differentially methylated regions (DMRs) in iMS cells versus AdMSCs [Fig. 2D(i)] with increased methylation at 158 and reduced methylation at 397 regions among all regions assessed [Fig. 2D(ii) and table S4G]. IPA of genes associated with these DMRs showed a notable overlap in annotated biological functions [Fig. 2D(iii) and table S4H] with those associated with differential H3K4me3, H3K27Ac, and H3K27me3 enrichment [Fig. 2C(iii) and table S4, E to G]. Together, these data imply that although basal transcriptomic differences between iMS cells and AdMSCs were limited, there were notable differences in epigenetic profiles at cis-regulatory regions of genes that were associated with cellular growth and systems development.

We next compared iMS cells to adipocytes from which they were derived. Expression of genes associated with adipogenesis was depleted in iMS cells (fig. S4A and table S4I). The promoter regions of these genes in iMS cells had broadly retained an active histone mark (H3K4me3), but, in contrast with adipocytes, many had acquired an inactive mark (H3K27me3) (fig. S4B and table S4J). However, there were examples where iMS cells had lost active histone marks (H3K4me3 and H3K27ac) at gene promoters and potential regulatory regions and gained repressive H3K27me3 [e.g., ADIPOQ; fig. S4C(i)]. In contrast, stromal genes had acquired active histone marks and lost repressive H3K27me3 [e.g. EPH2A; fig. S4C(ii)]. It is noteworthy that promoter regions of genes associated with muscle and pericytes (table S4K) were enriched for active histone marks in iMS cells compared with adipocytes [fig. S4D, (i) and (ii)]. We also compared demethylated CpGs in iMS cells and adipocytes (fig. S4E). There were 7366 sites in 2971 genes that were hypomethylated in iMS cells, of which 236 showed increased expression and were enriched for genes associated with tissue development and cellular growth and proliferation (fig. S4E).

PDGF-AB/AZAtreated murine osteocytes (murine iMS cells), but not bone-derived MSCs, expressed pluripotency associated genes, which were detectable by immunohistochemistry in 1 to 4% of cells (14). To evaluate expression in reprogrammed human cells, PDGF-AB/AZAtreated human adipocytes and matched AdMSCs were stained for OCT4, NANOG, and SOX2 with expression noted in 2, 0.5, and 3.5% of iMS cells respectively, but no expression was detected in AdMSCs (Fig. 2E). In addition to these transcription factors, we also evaluated surface expression of TRA-1-60 and SSEA4. Both proteins were uniformly expressed on iPSCs and absent in AdMSCs [fig. S4F(i)] and adipocytes [fig. S4F(ii)]. Although TRA-1-60 was absent in iMS cells, most (78%) expressed SSEA4 but rarely (<1%) coexpressed OCT4 and NANOG [fig. S4F(i)].

MSCs can be induced to differentiate in vitro into various cell lineages in response to specific cytokines and culture conditions. To evaluate the in vitro plasticity of human iMS cells, we induced their differentiation along with matched AdMSCs and primary adipocytes, into bone, fat, and cartilage, as well as into other mesodermal Matrigel tube-forming assays for endothelial cells (CD31) and pericytes (PDGFR) and muscle (MYH, myosin heavy chain; SMA, smooth muscle actin), endodermal (hepatocyte; HNF4, hepatocyte nuclear factor ), and neuroectodermal (TUJ1; neuron specific class III beta tubulin) lineages (Fig. 2F and fig. S4G). Whereas primary adipocytes remained as such and were resistant to transdifferentiation, iMS cells and AdMSCs showed comparable differentiation potential with the notable exception that only iMS cells generated pericyte-lined endothelial tubes in Matrigel. In keeping with these findings, relative to AdMSCs, iMS cells showed permissive epigenetic marks at pericyte genes [increased H3K4me3 and H3K27Ac; EPHA2 and MCAM; fig. S4H(i); and reduced CpG methylation; NOTCH1, SMAD7, TIMP2, AKT1, and VWF; fig. S4H(ii)]. Together with the notable differences in epigenetic profiles, these functional differences and low-level expression of pluripotency genes in iMS cell subsets suggested that these cells could be more amenable than matched AdMSCs to respond to developmental cues in vivo.

To evaluate spontaneous teratoma formation and in vivo plasticity of iMS cells, we tagged these cells and their matched AdMSCs with a dual lentiviral reporter, LeGO-iG2-Luc2 (28), that expresses both green fluorescent protein (GFP) and luciferase under the control of the cytomegalovirus promoter (Fig. 3A). To test teratoma-initiating capacity, we implanted tagged cells under the right kidney capsules of NOD Scid Gamma (NSG) mice (n = 3 per treatment group) after confirming luciferase/GFP expression in cells in culture (fig. S5, A and B). Weekly bioluminescence imaging (BLI) confirmed retention of cells in situ [Fig. 3B(i)] with progressive reduction in signal over time [Fig. 3B(ii)] and the absence of teratomas in kidneys injected with either AdMSCs or iMS cells [Fig. 3B(iii)]. Injection of equivalent numbers of iPS cells and iPS + iMS cell mixtures (1:49) to approximate iMS fraction expressing pluripotency markers led to spontaneous tumor formation in the same timeframe [Fig. 3B(iii)].

(A) Generation of luciferase/GFP-reporter AdMSCs and iMS cells, and assessment of their in vivo function. (B) Assessment of teratoma initiating capacity; (i) bioluminescence images at 0, 2, 6, and 8 weeks after implantation of 1 106 matched AdMSCs and iMS cells (P2; RM0057; n = 2 per group) under the right kidney capsules. (ii) Quantification of bioluminescence. (iii) Gross kidney morphology 8 weeks following subcapsular implantation of cells (R) or vehicle control (L). (C) Assessment of in vivo plasticity in a posterior-lateral intertransverse lumbar fusion model; (i) bioluminescence images following lumbar implantation of 1 106 matched AdMSCs or iMS cells (P2; RM0038; n = 3 per group) at 1 and 365 days after transplant. (ii) Quantification of bioluminescence. (iii) Tissues (bone, cartilage, muscle, and blood vessels) harvested at 6 months after implantation stained with (left) hematoxylin and eosin or (right) lineage-specific anti-human antibodies circles/arrows indicate regions covering GFP and lineage markerpositive cells. Corresponding graphs show donor cell (GFP+) contributions to bone, cartilage, muscle, and blood vessels as a fraction of total (DAPI+) cells in four to five serial tissue sections. Bars indicate confidence interval, n = 3. Photo Credit: Avani Yeola, UNSW Sydney.

To evaluate whether iMS cells survived and integrated with damaged tissues in vivo, we implanted transduced human iMS cells and matched AdMSCs controls into a posterior-lateral intertransverse lumbar fusion mouse model (Fig. 3A) (29). Cells were loaded into Helistat collagen sponges 24 hours before implantation into the posterior-lateral gutters adjacent to decorticated lumbar vertebrae of NSG mice (n = 9 iMS and n = 9 AdMSC). Cell retention in situ was confirmed by intraperitoneal injection of d-luciferin (150 mg/ml) followed by BLI 24 hours after cell implantation, then weekly for the first 6 weeks and monthly up to 12 months from implantation [Fig. 3C(i)]. The BLI signal gradually decreased with time but persisted at the site of implantation at 12 months, the final assessment time point [Fig. 3C(ii)]. Groups of mice (n = 3 iMS and n = 3 AdMSC) were euthanized at 3, 6, and 12 months and tissues harvested from sites of cell implantation for histology and immunohistochemistry [Fig. 3C(iii)]. Although implanted iMS cells and AdMSCs were present and viable at sites of implantation at 3 months, there was no evidence of lineage-specific gene expression in donor human cells (fig. S5C). By contrast, at 6 months after implantation, GFP+ donor iMS cells and AdMSCs were shown to contribute to new bone (BMP2), cartilage (SOX9), muscle (MYH), and endothelium (CD31) at these sites of tissue injury [Fig. 3C(iii)]. The proportion of donor cells expressing lineage-specific markers in a corresponding tissue section was significantly higher in iMS cells compared with matched AdMSCs at 6 months [Fig. 3C(iii) and table S2] as well as 12 months (fig. S5, E and D, and table S2). There was no evidence of malignant growth in any of the tissue sections or evidence of circulating implanted GFP+ iMS cells or AdMSCs (fig. S5E). Together, these data show that implanted iMS cells were not teratogenic, were retained long term at sites of implantation, and contributed to regenerating tissues in a context-dependent manner with greater efficiency than matched AdMSCs.

Although appropriate to assess in vivo plasticity and teratogenicity of implanted cells, the posterior-lateral intertransverse lumber fusion mouse model is not suited to address the question of tissue-specific differentiation and repair in vivo. To this end, we used a muscle injury model (30) where necrosis was induced by injecting 10 M cardiotoxin (CTX) into the left tibialis anterior (TA) muscle of 3-month-old female severe combined immunodeficient (SCID)/Beige mice. CTX is a myonecrotic agent that spares muscle satellite cells and is amenable to the study of skeletal muscle regeneration. At 24 hours after injury, Matrigel mixed with either 1 106 iMS cells or matched AdMSCs (or no cells as a control) was injected into the damaged TA muscle. The left (injured) and right (uninjured control) TA muscles were harvested at 1, 2, or 4 weeks after injury to assess the ability of donor cells to survive and contribute to muscle regeneration without ectopic tissue formation (Fig. 4A; cohort A). Donor human iMS cells or AdMSCs compete with resident murine muscle satellite cells to regenerate muscle, and their regenerative capacity is expected to be handicapped not only by the species barrier but also by having to undergo muscle satellite cell commitment before productive myogenesis. Recognizing this, a cohort of mice was subject to a second CTX injection, 4 weeks from the first injury/cell implantation followed by TA muscle harvest 4 weeks later (Fig. 4A; cohort B).

(A) Generation of iMS and AdMSCs and their assessment in TA muscle injury model. (B) (i) Confocal images of TA muscle stained for human CD56+ satellite cells (red) and laminin basement membrane protein (green; mouse/human). Graph shows donor hCD56+ satellite cell fraction for each treatment group. (ii) Confocal images of TA muscle harvested at 4 weeks and stained for human spectrin (red) and laminin (green; mouse/human). For each treatment, the left panel shows a tile scan of the TA muscle and the right panel a high magnification confocal image. Graph shows contribution of mouse (M), human (H), or chimeric (C) myofibers in three to five serial TA muscle sections per mouse (n = 3 mice per treatment group). (C) Confocal images of TA muscle 4 weeks following re-injury with CTX, stained for human spectrin (red) and laminin (green; mouse/human). For each treatment, left panel shows a tile scan of the TA muscle, upper right panel a low-magnification image, and lower right panel a high magnification image of the area boxed above. Graph shows contribution of mouse (M), human (H), or chimeric (C) myofibers in three to five serial TA muscle sections per mouse (n = 3 mice per treatment group). Graph bars indicate confidence interval. *P < 0.05, **P < 0.01, and ***P < 0.001 (linear mixed model). Photo credit: Avani Yeola, UNSW Sydney.

In tissue sections harvested from cohort A, donor-derived muscle satellite cells (31) [hCD56 (Thermo Fisher Scientific, MA5-11563)+; red] were evident in muscles implanted with both iMS cells and AdMSCs at each time point but were most numerous at 2 weeks after implantation [Fig. 4B(i) and fig. S6A]. The frequency of hCD56+ cells relative to total satellite cells [sublaminar 4,6-diamidino-2-phenylindolepositive (DAPI+) cells] was quantified in three to five serial sections of TA muscles per mouse in each of three mice per treatment group and was noted to be higher following the implantation of iMS cells compared with AdMSCs at all time points [week 1, 5.6% versus 2.4%; week 2, 43.3% versus 18.2%; and week 4, 30.7% versus 14.6%; Fig. 4B(i), table S2, and fig. S6A]. Donor cell contribution to regenerating muscle fibers was also assessed by measuring human spectrin (32) costaining with mouse/human laminin [(33) at 4 weeks (Fig. 4B(ii)]. At least 1000 myofibers from three to five serial sections of TA muscles for each of three mice in each treatment group were scored for human [H; hSpectrin+ (full circumference); laminin+], murine (M; mouse; hSpectrin; laminin+), or mouse/human chimeric [C; hSpectrin+ (partial circumference); laminin+] myofibers. Although none of the myofibers seen in cross section appeared to be completely human (i.e., donor-derived), both iMS cells and AdMSCs contributed to chimeric myofibers [Fig. 4B(ii)]. iMS cell implants contributed to a substantially higher proportion of chimeric fibers than AdMSC implants (57.7% versus 30.7%; table S2). In cohort B, TA muscles were allowed to regenerate following the initial CTX injection/cell implantation, and re-injured 4 weeks later with a repeat CTX injection. In these mice, although total donor cell contributions to myofibers in TA muscles harvested 4 weeks after re-injury were comparable to that observed in cohort A, there were no myofibers that appeared to be completely human (Fig. 4C). There were substantially more human myofibers following iMS cell implants than with AdMSCs (9.7% versus 5.4%; table S2). There was no evidence of ectopic tissue formation in TA muscles following implantation of either iMS cells or AdMSCs in either cohort.

To assess the physiological properties of muscles regenerated with human myofibers, we performed tetanic force contractions in extensor digitorum longus (EDL) muscles following the schema shown in Fig. 4A. Tetanic forces evoked by electrical pulses of various stimulus frequencies were not significantly different between the experimental cohorts or between the experimental cohorts and control animals [fig. S6B, (i) to (iii)]. However, when challenged with a sustained train of electrical pulses [fig. S6C(i)], the iMS group demonstrated significantly greater absolute [fig. S6C(ii)] and specific [fig. S6C(iii)] forces over a 3- to 6-s period. Together, these data showed that iMS cells had the capacity to respond appropriately to the injured environment and contribute to tissue-specific regeneration without impeding function.

We have optimized a protocol, originally designed for mouse osteocytes, to convert human primary adipocytes into iMS cells. We show that these long-term repopulating cells regenerate tissues in vivo in a context-dependent manner without generating ectopic tissues or teratomas.

PDGF-AB, AZA, and serum are indispensable ingredients in reprograming media, but the underlying reasons for their cooperativity and the observed dose-response variability between patients are not known. PDGF-AB is reported to bind and signal via PDGFR- and PDGFR- but not PDGFR- subunits (21). Mouse osteocytes and human adipocytes lack PDGFR, although surface expression was detectable as cells transition during reprogramming [mouse; day 2 of 8 (14) and human day 21 of 25]. However, these cells express PDGFR (14). Given that PDGFR inhibition attenuates iMS cell production in both mice (14) and humans, a degree of facilitated binding of PDGF-AB to PDGF- subunits or signaling through a noncanonical receptor is likely to occur, at least at the start of reprogramming. PDGF-Bcontaining homo- and heterodimers are potent mitogens that increase the pool of undifferentiated fibroblasts and preosteoblasts with rhPDGF-BB used in the clinic to promote healing of chronic ulcers and bone regeneration (34). However, the unique characteristics of PDGF-AB but not PDGF-BB or PDGF-AA that facilitate reversal and plasticity of cell identity in combination with AZA and serum (14) remain unknown.

PDGF-AB was replenished in culture throughout the reprogramming period, but AZA treatment was limited to the first 2 days for both mouse osteocyte and human adipocyte cultures. DNA replication is required for incorporation of AZA into DNA (35) and hence DNA demethylation is unlikely to be an initiating event in the conversion of terminally differentiated nonproliferating cells such as osteocytes and mature adipocytes. However, the majority of intracellular AZA is incorporated into RNA, which could directly affect the cellular transcriptome and proteome as an early event (36, 37). It is feasible that subsequent redistribution of AZA from RNA to DNA occurs when cells replicate resulting in DNA hypomethylation as a later event (38).

In the absence of serum, we could neither convert primary human adipocytes into iMS cells nor perpetuate these cells long term in culture. The efficiency of conversion and expansion was significantly higher with human versus FCS and highest with AS. The precise serum factor(s) that are required for cell conversion in conjunction with PDGF-AB and AZA are not known. The volumes of blood (~50 ml 2) and subcutaneous fat (5 g) that we harvested from donors were not limiting to generate sufficient numbers of P2 iMS cells (~10 106) for in vivo implantation and are in the range of cell numbers used in prospective clinical trials using mesenchymal precursor cells for chronic discogenic lumbar back pain (NCT02412735; 6 106) and hypoplastic left heart syndrome (NCT03079401; 20 106).

Our motivation was to optimize a protocol that could be applied to primary uncultured and easily accessible cells for downstream therapeutic applications, and adipose tissue satisfied these criteria. We have not surveyed other human cell types for their suitability for cell conversion using this protocol. It would be particularly interesting to establish whether tissue-regenerative properties of allogeneic mesenchymal precursor populations that are currently in clinical trials could be boosted by exposure to PDGF-AB/AZA. However, given that iMS cells and MSCs share stromal cell characteristics, identifying a unique set of cell surface markers that can distinguish the former is a priority that would assist in future protocol development and functional assessment of iMS cells.

Producing clinical-grade autologous cells for cell therapy is expensive and challenging requiring suitable quality control measures and certification. However, the advent of chimeric antigen receptor T cell therapy into clinical practice (39) has shown that production of a commercially viable, engineered autologous cellular product is feasible where a need exists. Although there were no apparent genotoxic events in iMS cells at P2, ex vivo expansion of cells could risk accumulation of such events and long-term follow-up of ongoing and recently concluded clinical trials using allogeneic expanded mesenchymal progenitor cells will be instructive with regard to their teratogenic potential. The biological significance of the observed expression of pluripotency-associated transcription factors in 2 to 3% of murine and human iMS cells is unknown and requires further investigation. However, their presence did not confer teratogenic potential in teratoma assays or at 12-month follow-up despite persistence of cells at the site of implantation. However, this risk cannot be completely discounted, and the clinical indications for iMS or any cell therapy require careful evaluation of need.

In regenerating muscle fibers, it was noteworthy that iMS cells appeared to follow canonical developmental pathways in generating muscle satellite cells that were retained and primed to regenerate muscle following a second muscle-specific injury. Although iMS cells were generated from adipocytes, there was no evidence of any adipose tissue generation. This supports the notion that these cells have lost their native differentiation trajectory and adopted an epigenetic state that favored response to local differentiation cues. The superior in vivo differentiation potential of iMS cells vis--vis matched AdMSCs was consistent with our data showing that despite the relatively minor transcriptomic differences between these cell types, the epigenetic state of iMS cells was better primed for systems development. Another clear distinction between iMS cells and AdMSCs was the ability of the former to produce CD31+ endothelial tube-like structures that were enveloped by PDGFR+ pericytes. An obvious therapeutic application for iMS cells in this context is vascular regeneration in the setting of critical limb ischemia to restore tissue perfusion, an area of clear unmet need (40).

An alternative to ex vivo iMS cell production and expansion is the prospect of in situ reprogramming by local subcutaneous administration of the relevant factors to directly convert subcutaneous adipocytes into iMS cells, thereby eliminating the need for ex vivo cell production. AZA is used in clinical practice and administered as a daily subcutaneous injection for up to 7 days in a 28-day cycle, with responders occasionally remaining on treatment for decades (41). Having determined the optimal dose of AZA required to convert human adipocytes into iMS cells in vitro (2 days, 5 M), the bridge to ascertaining the comparable in vivo dose would be to first measure levels of AZA incorporation in RNA/DNA following in vitro administration and match the dose of AZA to achieve comparable tissue levels in vivo. A mass spectrometrybased assay was developed to measure in vivo incorporation of AZA metabolites (AZA-MS) in RNA/DNA and is ideally suited to this application (38). The duration of AZA administration for adipocyte conversion was relatively short (i.e., 2 days), but PDGF-AB levels were maintained for 25 days. One mechanism of potentially maintaining local tissue concentrations would be to engineer growth factors to bind extra cellular matrices and be retained at the site of injection. Vascular endothelial growth factor A (VEGF-A) and PDGF-BB have recently been engineered with enhanced syndecan binding and shown to promote tissue healing (42). A comparable approach could help retain PDGF-AB at the site of injection and maintain local concentrations at the required dose. While our current data show that human adipocytederived iMS cells regenerate tissues in a context-dependent manner without ectopic or neoplastic growth, these approaches are worth considering as an alternative to an ex vivo expanded cell source in the future.

Extended methods for cell growth and differentiation assays and animal models are available in the Supplementary Materials, and antibodies used are detailed in the relevant sections.

The primary objective of this study was to optimize conditions that were free of animal products for the generation of human iMS cells from primary adipocytes and to characterize their molecular landscape and function. To this end, we harvested subcutaneous fat from donors across a broad age spectrum and used multiple dose combinations of a recombinant human growth factors and a hypomethylating agent used in the clinic and various serum types. We were particularly keen to demonstrate cell conversion and did so by live imaging and periodic flow cytometry for single-cell quantification of lipid loss and gain of stromal markers. Using our previous report generating mouse iMS cells from osteocytes and adipocytes as a reference, we first characterized the in vitro properties of human iMS cells including (i) long-term growth, (ii) colony-forming potential, (iii) in vitro differentiation, and (iv) molecular landscape. Consistent with their comparative morphology, cell surface markers, and behavioral properties, the transcriptomes (RNA sequencing) were broadly comparable between iMS cells and matched AdMSCs, leading to investigation of epigenetic differences [Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) histone chromatin immunoprecipitation sequencing (ChIP-seq), and RRBS for DNA methylation differences] that might explain properties that were unique to iMS cells (expression of pluripotency factors, generation of endothelial tubes in vitro with pericyte envelopes, and in vivo regenerative potential). Context-dependent in vivo plasticity was assessed using a tissue injury model that was designed to promote bone/cartilage/muscle/blood vessel contributions from donor cells and simultaneously assess the absence of ectopic/malignant tissue formation by these cells (labeled and tracked in vivo using a bioluminescence/fluorescence marker). Tissue-specific regeneration and the deployment of canonical developmental pathways were assessed using a specific muscle injury model, and donor cell contributions in all injury models were performed on multiple serial tissue sections in multiple mice with robust statistical analyses (see below). Power calculations were not used, samples were not excluded, and investigators were not blinded. Experiments were repeated multiple times or assessments were performed at multiple time points. Cytogenetic and Copy Number Variation (CNV) analyses were performed on iMS and AdMSCs pretransplant, and their teratogenic potential was assessed both by specific teratoma assays and long-term implantation studies.

Subcutaneous fat and blood were harvested from patients undergoing surgery at the Prince of Wales Hospital, Sydney. Patient tissue was collected in accordance with National Health and Medical Research Council (NHMRC) National Statement on Ethical Conduct in Human Research (2007) and with approval from the South Eastern Sydney Local Health District Human Research Ethics Committee (HREC 14/119). Adipocytes were harvested as described (43). Briefly, adipose tissue was minced and digested with 0.2% collagenase type 1 (Sigma-Aldrich) at 37C for 40 min and the homogenized suspension passed through a 70-m filter, inactivated with AS, and centrifuged. Primary adipocytes from the uppermost fatty layer were cultured using the ceiling culture method (44) for 8 to 10 days. AdMSCs from the stromal vascular pellet were cultured in MEM + 20% AS + penicillin (100 g/ml) and streptomycin (250 ng/ml), and 200 mM l-glutamine (complete medium).

Adherent mature adipocytes were cultured in complete medium supplemented with AZA (R&D systems; 5, 10, and 20 M; 2 days) and rhPDGF-AB (Miltenyi Biotec; 100, 200, and 400 ng/ml; 25 days) with medium changes every 3 to 4 days. For inhibitor experiments, AG1296 was added for the duration of the culture. Live imaging was performed using an IncuCyte S3 [10 0.25numerical aperture (NA) objective] or a Nikon Eclipse Ti-E (20 0.45-NA objective). Images were captured every 30min for a period of 8 days starting from day 15. Twelve-bit images were acquired with a 1280 1024 pixel array and analyzed using ImageJ software. In vitro plasticity was determined by inducing the cells to undergo differentiation into various cell types using differentiation protocols adapted from a previous report (45).

Animals were housed and bred with approval from the Animal Care and Ethics Committee, University of New South Wales (UNSW; 17/30B, 18/122B, and 18/134B). NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) and SCID/Beige (C.B-Igh-1b/GbmsTac-Prkdcscid-Lystbg N, sourced from Charles River) strains were used as indicated. The IVIS Spectrum CT (Perkin Elmer) was used to capture bioluminescence. Briefly, 15 min after intraperitoneal injection of d-luciferin (150 mg/kg), images were acquired for 5 min and radiance (photon s1 cm2 sr1) was used for subsequent data analysis. The scanned images were analyzed using the Living Image 5.0 software (Perkin Elmer).

Teratoma assays (46) were performed on 3- to 4-month-old female NSG mice. Lentiviral-tagged cells (5 105) in 20 l of phosphate-buffered saline containing 80% Matrigel were injected under the right kidney capsule using a fine needle (26 gauges) and followed weekly by BLI until sacrifice at week 8. Both kidneys were collected, fixed in 4% paraformaldehyde (PFA) for 48 hours, embedded in optimal cutting temperature compound (OCT), cryosectioned, and imaged for GFP.

Posterior-lateral intervertebral disc injury model (29). Lentiviral-tagged (28) AdMSCs (1 106) or iMS cells were loaded onto Helistat collagen sponges and implanted into the postero-lateral gutters in the L4/5 lumbar spine region of anesthetized NSG mice following decortication of the transverse processes. Animals were imaged periodically for bioluminescence to track the presence of transplanted cells. At 3, 6, or 12 months, mice were euthanized, and spines from the thoracic to caudal vertebral region, including the pelvis, were removed whole. The specimens were fixed in 4% PFA for 48 hours, decalcified in 14% (w/v) EDTA, and embedded in OCT.

Muscle injury model (47). The left TA and EDL muscles of 3- to 4-month-old female SCID/Beige mice were injured by injection with 15 l of 10 M CTX (Latoxan). Confocal images of three to four serial sections (TA) per mouse were captured by Zen core/AxioVision (Carl Zeiss) and visualized by ImageJ with the colocalization and cell counter plugins [National Institutes of Health; (48)]. Tetanic force contractions were performed on EDL muscles (49).

Total RNA was extracted using the miRNeasy Mini Kit (Qiagen) according to manufacturers instructions, and 200 ng of total RNA was used for Illumina TruSeq library construction. Library construction and sequencing was performed by Novogene (HK) Co. Ltd. Raw paired-end reads were aligned to the reference genome (hg19) using STAR (https://github.com/alexdobin/STAR), and HTSeq (50) was used to quantify the transcriptomes using the reference refFlat database from the UCSC Table Browser (51). The resulting gene expression matrix was normalized and subjected to differential gene expression using DeSeq2 (52). Normalized gene expression was used to compute and plot two-dimensional principal components analysis, using the Python modules sklearn (v0.19.1; https://scikit-learn.org/stable/) and Matplotlib (v2.2.2; https://matplotlib.org/), respectively. Differentially expressed genes (log2 fold change |1|, adjusted P < 0.05) were the input to produce an unsupervised hierarchical clustering heat map in Partek Genomics Suite software (version 7.0) (Partek Inc., St. Louis, MO, USA). Raw data are available using accession GSE150720.

ChIP was performed as previously described (53) using antibodies against H3K27Ac (5 g per IP; Abcam, ab4729), H3K4Me3 (5 g per IP; Abcam ab8580), and H3K27Me3 (5 g per IP; Diagenode, C15410195). Library construction and sequencing were performed by Novogene (HK) Co. Ltd. Paired-end reads were aligned to the hg38 genome build using Burrows Wheeler Aligner (BWA) (54) duplicate reads removed using Picard (http://broadinstitute.github.io/picard/), and tracks were generated using DeepTools bamCoverage (https://deeptools.readthedocs.io/en/develop/). Peaks were called using MACS2 (55) with the parameter (P = 1 109). Differentially bound regions between the AdMSC and iMS were calculated using DiffBind (http://bioconductor.org/packages/release/bioc/vignettes/DiffBind/inst/doc/DiffBind.pdf) and regions annotated using ChIPseeker (56). Raw data are available using accession GSE151527. Adipocyte ChIP data were downloaded from Gene Expression Omnibus (GEO); accession numbers are as follows for the three histone marks: GSM916066, GSM670041, and GSM772771.

Total genomic DNA was extracted using the DNA MiniPrep Kit (Qiagen), and RRBS library construction and sequencing were performed by Novogene (HK) Co. Ltd. Raw RRBS data in fastq format were quality and adapter trimmed using trim_galore (0.6.4) with rrbs parameter (www.bioinformatics.babraham.ac.uk/projects/trim_galore). The trimmed fastq files were then aligned to a bisulfite-converted genome (Ensembl GRCh38) using Bismark (2.3.5), and methylation status at each CpG loci was extracted (57). The cytosine coverage files were converted to BigWig format for visualization. Differentially methylated cytosines (DMCs) and DMRs were identified using methylKit (1.10) and edmr (0.6.4.1) packages in R (3.6.1) (58, 59). DMCs and DMRs were annotated using ChIPseeker (56), and pathway enrichment was performed as detailed below. Raw data are available using accession number GSE151527. Adipocyte RRBS data were downloaded from GEO: GSM2342293 and GSM2342392.

IPA (Qiagen) was used to investigate enrichment in molecular and cellular functions, systems development and function, and canonical pathways.

Statistical analysis was performed in SAS. For the dose-optimization experiments (Fig. 1), a linear mixed model with participant-level random effects was used to estimate maximum time by dose level and age group. A linear mixed model with participant-level random effects was used to analyze statistical differences in lineage contribution outcomes between treatment groups (Fig. 3) and at different time points posttransplant, to estimate the percentage of cells by treatment and lineage. For the in vivo regeneration experiment (Fig. 4), a linear model was used to model the percent of cells over time for each group. Quadratic time terms were added to account for the observed increase from 1 to 2 weeks and decrease from 2 to 4 weeks. In the muscle regeneration experiment, a linear model was applied to cohort A and cohort B, to estimate and compare percent cells by treatment and source. Statistical modeling data are included in table S2.

Acknowledgments: We are indebted to the patients who donated tissue to this project. We thank E. Cook (Prince of Wales Private Hospital), B. Lee (Mark Wainwright Analytical Centre, UNSW Sydney), and technicians at the UNSW BRC Facility for assistance with sample and data collection and animal care; Y. Huang for technical assistance; and A. Unnikrishnan and C. Jolly for helpful discussions and critical reading of the manuscript. We acknowledge the facilities and scientific and technical assistance of the National Imaging Facility, a National Collaborative Research Infrastructure Strategy (NCRIS) capability, at the BRIL (UNSW). The STRO-1 antibody was a gift from S. Gronthos, University of Adelaide, Australia. Funding: We acknowledge the following funding support: A.Y. was supported by an Endeavour International Postgraduate Research scholarship from the Australian Government. S.S. is supported by an International Postgraduate Student scholarship from UNSW and the Prince of Wales Clinical School. P.S. is supported by an International Postgraduate Student scholarship from UNSW. M.L.T. and D.D.M. acknowledge funding from St. Vincents Clinic Foundation and Arrow BMT Foundation. K.A.K. acknowledges funding from Australian Research Council (FT180100417). J.M. is supported, in part, by the Olivia Lambert Foundation. M.K. is supported by a NHMRC Program Grant (APP1091261) and NHMRC Principal Research Fellowship (APP1119152). L.B.H. acknowledges funding from MTPConnect MedTech and Pharma Growth Centre (PRJ2017-55 and BMTH06) as part of the Australian Governmentfunded Industry Growth Centres Initiative Programme and The Kinghorn Foundation. D.B. is supported by a Peter Doherty Fellowship from the National Health and Medical Research Council of Australia, a Cancer Institute NSW Early Career Fellowship, the Anthony Rothe Memorial Trust, and Gilead Sciences. R.M. acknowledges funding from Jasper Medical Innovations (Sydney, Australia). J.E.P., V.C., and E.C.H. acknowledge funding from the National Health and Medical Research Council of Australia (APP1139811). Author contributions: The project was conceived by V.C. and J.E.P., and the study design and experiments were planned by A.Y., V.C., and J.E.P. Most of the experiments and data analyses were performed by A.Y., guided and supervised by V.C. and J.E.P. S.S., R.A.O., C.A.L., D.C., F.Y., M.L.T., P.S., T.H., J.R.P., P.H., W.R.W., and V.C. performed additional experiments and data analyses, with further supervision from R.M., C.P., J.A.I.T., D.C., J.W.H.W., L.B.H., D.B., and E.C.H. Statistical analyses were performed by J.O. R.M., D.D.M., J.M., K.A.K., and M.K. provided critical reagents. The manuscript was written by A.Y., J.A.I.T., V.C., and J.E.P., and reviewed and agreed to by all coauthors. Competing interests: V.C. and J.E.P. are named inventors on a patent A method of generating cells with multi-lineage potential (US 9982232, AUS 2013362880). All other authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

See the original post here:
Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances

The immune system and COVID-19 – Shawnee Mission Post

Our body needs a healthy immune system to defend itself against germs. In the midst of the COVID-19 pandemic and flu season, you need a healthy immune system more than ever.

Tereza Hubkova, MD, ABIHM, ABIM, is an integrative medicine physician at AdventHealth Shawnee Mission. According to Dr. Hubkova, our immune system is strongly influenced by our lifestyle: the foods we eat, how we sleep, our physical activity and even our mood and level of stress.

Proper nutrition is key. You want to make sure your diet provides all the nutrients your immune system needs and that your body is not in a pro-inflammatory state in case you would catch COVID.

The life-threatening complication of COVID, the cytokine storm, happens when the immune system goes into overdrive and the immune response itself causes too much collateral damage. Our Western diet full of processed foods, sugar, salt and unhealthy fat puts many Americans at risk. Instead, we need fresh produce full of vitamins and colorful polyphenols, minerals, fiber, protein and healthy fats (including omega 3 fatty acids from seafood).

Our age affects our immune system as well children and young adults are less likely to be affected by COVID than older people.

Even just one night of poor sleep severely impairs our ability to deal with viruses, said Dr. Hubkova. When partially sleep deprived, we produce 75 percent less natural killer cells that could eliminate viruses. As we get older, we also produce less melatonin, a hormone crucial for a healthy immune system. Stress and blue light from our electronic screens suppress melatonin production as well.

Dr. Hubkova also advises to be sure your Vitamin D level is in the optimal range.

Patients in intensive care due to severe COVID almost always have low vitamin D level, said Dr. Hubkova.

We make Vitamin D in our skin when we are exposed to sunshine, but our modern indoor lifestyle means that Vitamin D deficiency is extremely common. We do not get much Vitamin D from food, so besides spending more time outdoors, taking a Vitamin D supplement may be the next best solution, especially in the winter.

Between the COVID pandemic and cold weather, many people are not getting out much and interacting with others, which is likely contributing to anxiety and depression and affecting our immune system as well.

Our immune system has receptors for the molecules of emotion, said Dr. Hubkova. It knows when we are happy or sad, and it works much better when we are in a positive state of mind.

Finally, is there any advice for COVID vaccination?

In general, we do not respond well to vaccines when our immune system is weakened, such as by stress or sleep deprivation, said Dr. Hubkova. While we do not know everything about the COVID vaccine yet, try to get a good nights sleep the night before you get vaccinated.

Dr. Hubkova has created the 21-day immunity challenge designed to get your immune system in better working order by addressing a few key lifestyle habits, one day at a time. Learn more about the 21-day immunity challenge at MyHealthKC.com.

Link:
The immune system and COVID-19 - Shawnee Mission Post

Learn How Diet & Supplements Can Jump Start Your System For Better Overall Health With The East West Way – KXAN.com

Posted: Jan 18, 2021 / 12:02 PM CST / Updated: Jan 18, 2021 / 12:02 PM CST

Wellness Expert Taz Bhatia, MD. Explains How to Put Yourself Back Together & Recover from the Stresses of 2020

2020 has been a very stressful year with challenges that we havent faced in recent times. We have collectively experienced trauma which can wreck havoc on the body, and as a result, many people are experiencing new health issues. So, how do we recover? We have one of the top integrative medicine physicians in the nation available to share timely tips for making a full recovery from 2020 and getting back on track for 2021.

Dr. Taz Bhatia will tackle a critical topic as we move into the New Year. Shell share her 2020 Recovery Checklist and explain how some new supplements can help with better sleep, boost energy, lose weight and maintain overall health. Dr. Bhatias practice is nationally recognized for creating specialized treatments plans. Her unique approach has earned her guest appearances on the Today Show, Dr. Oz, and numerous other network TV shows. Some of her best-selling books include: WHATDOCTORS EAT, THE 21-DAY BELLY FIX and SUPER WOMAN RX.

Dr. Taz Bhatia, M.D. is an integrative medicine physician and wellness expert who gained national recognition as a best-selling author of the books, What Doctors Eat, The 21 Day Belly Fix, and Super Woman Rx. Her integration of Eastern medical wisdom with modern science has led to featured segments on The Today Show, Dr. Oz, Live with Kelly & Ryan and eventually the premiere of her own PBS special Super Woman RX with Dr. Taz. She is also the host of the Super Woman Wellness with Dr. Taz podcast. Personal health challenges in her twenties led Dr. Bhatia to opening her now nationally recognized practice. Today, Dr. Taz and her team work to help patients understand their core health issues and develop personalized treatment plans, pulling from multiple systems of medicine, including integrative, functional, Chinese, and holistic medicine.

For more information visit TheEastWestWay.com & DoctorTaz.com.

Sponsored by The East West Way. Opinions expressed by the guest(s) on this program are solely those of the guest(s) and are not endorsed by this television station.

Excerpt from:
Learn How Diet & Supplements Can Jump Start Your System For Better Overall Health With The East West Way - KXAN.com

Rebound: The power of the great outdoors and improved mental health – Fox17

GRAND RAPIDS We all know the past year has tested our mental health in new ways and now in the middle of winter, it can become even more a challenge. But the power of the great outdoors could be more beneficial than you realize. Studies show that just five minutes of outdoor exposure can lead to improved mental health.

We're finding that spending time in nature actually boosts our immune system by strengthening our levels and numbers of natural killer cells. And that is so important right now, because we know that our body needs to have a strong immune system, says Suzanne Bartlett Hackenmiller, M.D who is an OB-GYN and Integrative Medicine physician.

A number of studies are finding that there's something magical about the 20 minute mark, and that 20 minutes of time in nature at doing the activity of your choice can again reduce salivary amylase and cortisol levels, these stress hormones. Another one found that spending time in nature reduced rumination, which is that concept of just repeating thoughts in your mind that you can't stop, this cycle of stressful thoughts, and that rumination is associated with anxiety and depression, she said.

This is also something that can be accomplished in the middle of winter. Studies have show that people are able to derive health benefits in fairly unlikely ways.

It might be sitting on your porch, it might be looking out your window, and being able to take some time to just slowly go through the senses. And just notice what you're seeing, what you're hearing, what you're feeling in a tactile way. This can even be done with an indoor potted plant, if you can believe that. And just taking the time, we talk in forest bathing about the concept of a sit spot, which is spending 20 minutes with no agenda, doing nothing other than just seeing what you see, hearing what you hear, noticing what you notice about nature around you and it can be done really anywhere.

This is something that can be very beneficial for children too, especially during these times. Holistic Child Psychologist, Dr. Nicole Beurkens says it improves focus, attention, learning, anxiety and mood.

Just a five minute reset of saying to our kids during a hectic day of virtual learning, or their attentions not so good, or they're just in an irritable mood, go outside, even in the cold. Even just being outdoors in that space for five minutes can be a great shift. Then when we come back inside, our kids come back in and can get back into what they were doing and just have their brain and their body be in a better place to do that. So it doesn't have to be a long drawn out thing, we think oh, you know, this is going to be a hassle but it can be quick, it can be easy.

Plus, its free and there is a lot of it.

If I were to give just a recommendation, a prescription for time spent in nature, which I do prescribe to all of my patients, it would be to come up with something that you enjoy doing for even small, small increments of time and treat it as a prescription. It might be that you decide, what it is your your prescription, your medicine and how often you do it on a regular basis." said Dr. Hackenmiller.

Dr. Beurkens and Dr. Hackenmiller have a podcast if you want to learn more about forest bathing, you can find that here.

For more information click here.

Visit link:
Rebound: The power of the great outdoors and improved mental health - Fox17

The #1 Best Tea for Fat Loss, According to Nutritionists | Eat This Not That – Eat This, Not That

The best tea for fat loss is any plain unsweetened tea that you choose to drink instead of some other unhealthy beverages like these belly busters: sweet tea, soda, juice, smoothies, beer, etc.). (For more background, here are 7 Ways Tea Can Help You Lose Weight.)

Disappointed with that answer? Don't be. It's the honest truth: If you are looking for a magic bullet for weight loss, you won't find it in a teacup. Drinking tea alone is no more effective than any other fat-loss technique if you don't combine it with other healthy eating practices. In other words, a cuppa plain tea won't cancel out the tea biscuits.

That said, unsweetened tea is second only to water as the weight loss beverage most recommended by nutritionists and other health experts. For good reason: Plain tea contains zero calories and is rich in natural compounds that have many health benefits.

But which is the best type of tea for fat loss? One could argue that green tea is tops simply because green tea has been clinically studied more than any other kind of tea. Many studies have shown that the bounty of antioxidants in green tea may reduce inflammation and lower the risk of heart disease, diabetes, and cancer. Research suggests that special compounds called catechins and the caffeine in green tea stimulate thermogenesis and boost metabolism. Other studies correlate drinking several cups of green tea a day for longer than six weeks with weight loss.

Of course, any calorie-free tea can help with weight loss if it replaces a high-calorie beverage. To get the biggest fat-loss benefit from tea, pick your favorite from these tea types recommended by nutritionists and pair it with one of The 6 Best Diets That Will Make You Live Longer.

"One of the best teas that support fat loss is black tea," says Tiffany Joy Yamut, a registered nurse, certified nutritionist, and co-founder of the keto diet resource Ketogenic Buddies. Black tea is made from leaves of the same plant from which green tea is made:Camellia sinensis. The big difference is how it's processed. Black tea leaves are exposed to air and allowed to oxidize into that trademark dark brown color. "A 2016 study published in Molecules showed that polyphenols in black tea can prevent obesity; one of its mechanisms is that it inhibits lipid (fat) absorption," says Yamut. "I follow a low-carbohydrate diet and black tea suits my lifestyle well since it contains no carbs plus some caffeine to jumpstart my metabolism." However, black tea isn't for everyone, she cautions. "Tea has caffeine, which can worsen gastroesophageal reflux disease symptoms."

RELATED: Sign up for our newsletter to get daily recipes and food news in your inbox!

"Any plain tea without sugar, honey, and syrups is great for weight loss," says Amanda A Kostro Miller, RD, LDN, who serves on the advisory board for Fitter Living. "Not only can you get fluid for hydration, [but you're also] filling up your stomach for only a few calories." If you run out of tea, you can always hydrate for fat loss by knowing This Is How Much Water You Need to Drink for Weight Loss.

This traditional Chinese tea, also known as black dragon, is made from the leaves of the same plant that yields green and black teas. The only difference is that unlike green tea, oolong is allowed to oxidize, but not long enough to turn into black tea. The result is a flavor that is less bitter than black tea, lighter, and more "grassy." Oolong tea has not been studied to the extent of green tea, but studies do point to its potential as a weight-loss beverage. In one study published in the Chinese Journal of Integrative Medicine, 102 overweight people consumed 8 grams of oolong tea, or about four cups a day for six weeks. Measuring body fat and body weight levels, researchers found that 70% of the heaviest subjects lost a little more than 2 pounds while 22% lost more than 6.5 pounds. Also, 12% of subjects experienced a decrease in subcutaneous fat.

Plant-based nutritionist Stephanie Mantilla's favorite weight-loss tea is caffeine-free rooibos from South Africa. Studies have shown that the red tea "helps block the creation of fat cells and increase metabolism," says the founder of Plant Prosperous.

Because the herbal tea is high in antioxidants and contains anti-inflammatory properties, one South African researcher is investigating its effect on fat stem cells. Dr. Hanl Sadie-Van Gijsen of the Division of Medical Physiology at Stellenbosch University is seeking to addressthe inflammation and oxidative stress within the fat tissue to relieve whole-body inflammation and insulin resistance. She says inflammation and oxidative stress are hallmarks of "dysfunctional fat," and responsible for many of the diseases associated with obesity.

Peppermint is a time-honored home remedy for indigestion, and it is believed to be a metabolism booster. "This tea's antifungal nature is also responsible for its ability to help improve digestive health," says nutritionist Lisa Richards, author of The Candida Diet. "A cup of peppermint tea after a meal can help alleviate gas and bloating while also speeding along digestion and potentially metabolism through this means as well."

Ginger tea is a favorite of Trista Best, RD, a registered dietitian with Balance Once Supplements, due to its robust flavor and antioxidant richness. "Ginger is unique for weight loss in that it contains compounds known as gingerols and shogaols, compounds that reduce the oxidative stress that exacerbates obesity," she says. "This damage occurs at the cellular level and once those damaged cells replicate the body's natural processes that maintain homeostasis can become disrupted leading to decreased metabolism, energy, and more."

A number of experts told us that green tea, matcha (a powdered green tea), and green tea extract are considered to be some of the best for supporting healthy weight loss because they are particularly high in antioxidants and anti-inflammatory compounds including EGCG (epigallocatechin-3-gallate).

"EGCG seems to help block the formation of new fat cells and may also reduce hunger and cravings, plus caffeine in green tea has appetite-decreasing effects," says Dr. Josh Axe, D.N.M., CNS, founder of Dr.Axe.com.

This catechin abundant in green tea is also thought to improve recovery from exercise, boosting metabolism and potentially reducing fat storage. "Antioxidants found in green tea can support metabolic health by lowering oxidative stress, plus they keep blood sugar levels more balanced which is beneficial for controlling fat storage," says Axe.

"The ECGC in green tea can deactivate the genetic triggers for diabetes and obesity," says Kelly Choi, author of the Eat This, Not That! book The 7-Day Flat-Belly Tea Cleanse.

To learn how drinking green tea changed Choi's life, read I Tried a Tea Cleanse for 7 Days and This is What Happened.

See the original post here:
The #1 Best Tea for Fat Loss, According to Nutritionists | Eat This Not That - Eat This, Not That

The Trump administration gave more than $850,000 in PPP loans to prominent anti-vaccine groups – Business Insider India

Five top anti-vaccine advocacy organizations that have spread medical misinformation throughout the COVID-19 pandemic received funding from the Trump administration's Paycheck Protection Program (PPP), The Washington Post reported Monday.

The loans from the Small Business Administration totaled more than $850,000, according to the report.

"Lending money to these organizations so they can prosper is a sickening use of taxpayer money," Countering Digital Hate CEO Imran Ahmed told The Washington Post. "These groups are actively working to undermine the national COVID vaccination drive, which will create long-term health problems that are felt most acutely in minority communities and low-income neighborhoods."

Advertisement

Mercola, a businessman and doctor of osteopathic medicine, is himself a major donor of the NVIC. The Washington Post reported in 2019 that Mercola gave the NVIC $2.9 million, making up roughly 40% of the group's funding. Mercola has millions of followers on Facebook.

The Pew Research Center said in a December report that about 39% of Americans said they would definitely not, or probably not, get the vaccine. 21% of American adults surveyed said they were "pretty certain" that new information about COVID-19 vaccination would not change their minds.

Anti-vaccine advocacy groups have played a major role in propagating that distrust, Viswanath said.

See the article here:
The Trump administration gave more than $850,000 in PPP loans to prominent anti-vaccine groups - Business Insider India

Digital Health Coaching Market 2021-28 looming business opportunities at $7 billion with Aetna, American Association for Health Education, American…

Digital Health coaching has emerged worth $7 billion service market, with a strong growth outlook. An estimated 128,000 health coaches and health educators advise and motivate clients to change bad lifestyle habits and to manage chronic conditions such as diabetes. Consumers, employers and insurers are each now more seriously focused on improving health and being proactive, in light of the pandemic, rising obesity levels, and chronic health conditions.

Digital Health Coaching, conveniently offered online, is designed to deliver highly personalized, insight-driven behavior change programs to help your members better focus on their health and well-being. With periodic check-ins, these coaching programs are designed to encourage long-term engagement and participation.

According to the United States Bureau of Labor Statistics, there were 99,400 health educators and community health workers, including health coaches, employed nationwide in 2012. By 2022, this employment figure is projected to increase to 120,800, which expresses a +21% growth change.

Request a sample copy of report @ https://www.reportconsultant.com/request_sample.php?id=79910

A new market report documentation has been added with extensive research elements, evaluating the diverse growth propellants in the Digital Health Coaching Market. The report is a mindful representation of robust research activities undertaken by in-house research experts who have critically imbibed the output of various primary and secondary research endeavors in a bid to comprehend the impact of COVID-19 reflected upon the growth trajectory of the Digital Health Coaching market.

Key Players:

Owing to the sudden onset of dynamic macro-economic factors such as the outrage of COVID-19, the Digital Health Coaching market has been thoroughly affected by the current developments, thus manifesting in a myriad alterations and tangible deviations from the regular growth course of the Digital Health Coaching market.

A thorough analytical review of the pertinent growth trends influencing the Digital Health Coaching market has been demonstrated in the report to affect unbiased and time-efficient business discretion amongst various leading players, seeking a strong footing in the competitive landscape of the Digital Health Coaching market, which regularly gets influenced in a major way by the ongoing micro and macro-economic factors having a lingering set of implications on the growth trends of the aforementioned market.

Market Report Segmentation:

Get upto 40% Discount available on this Report @ https://www.reportconsultant.com/ask_for_discount.php?id=79910

The following sections of this versatile report on Digital Health Coaching market specifically sheds light on popular industry trends encompassing both market drivers as well as dominant trends that systematically affect the growth trajectory visibly. The report also sheds substantial light on all major key producers dominant in the Digital Health Coaching market, encompassing versatile details on facets such as production and capacity deductions. Substantial light has also been shed upon other key elements such as overall production, activities practiced by key players, best of the industry practices.

Key Benefits:

About Us:

Report Consultant A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative business in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered business all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the futuristic market.

Contact us:

Riaana Singh

(Report Consultant)

sales@reportconsultant.com

http://www.reportconsultant.com

View post:
Digital Health Coaching Market 2021-28 looming business opportunities at $7 billion with Aetna, American Association for Health Education, American...

Enzymedica Announces Newly Formed Scientific Advisory Board and the Appointment of Renowned Integrative Wellness Expert Dr. Mark Tager as a Key Member…

Dr. Mark Tager is an internationally recognized authority on integrative wellness and education.

VENICE, Fla. (PRWEB) January 14, 2021

Enzymedica, the leading natural digestive health and wellness brand, announced today that Mark Tager, MD, has joined the companys newly formed Scientific Advisory Board. Dr. Tager, who is on faculty at Duke Integrative Medicine, is an internationally recognized authority on integrative wellness and education. He brings tremendous value to the board with his expertise and experience. Enzymedicas Scientific Advisory Board, an evolutionary turning point within the natural products industry, will have three key focus areas: research and development, content development, and consumer and retailer education. In addition to Dr. Tager, the new board will include noted experts in their fields who will provide dynamic perspectives and advice. Each will contribute to driving awareness of the science and efficacy of Enyzmedicas high-quality and innovative products, while advancing new education programs promoting behavior modifications to achieve a healthier lifestyle.

As the CEO of San Diego-based healthcare consulting firm ChangeWell Inc. for the past 20 years, Dr. Tager has been a leader in delivering unique educational programs that reflect the powerful connection between health and human productivity. He also is a serial entrepreneur who has held executive positions at several prominent healthcare companies, delivered more than 1,000 seminars, and is an accomplished author of ten books. His latest book Cash-Pay Healthcare: How to Start, Grow & Perfect Your Business (with Stewart Gandolf, MBA) presents a business-oriented map for all health-related practitioners.

A pioneer in holistic healthcare, the first of his ten books he authored was titled Whole Person Healthcare, advocating an integrative approach to medicine. He started his career as Director of Health Promotion for Kaiser Permanente and was the producer of an early cable health series entitled The Wellness Lifestyle. He went on to found a consumer health company that was acquired by the noted Times Mirrors Mosby Health division. In addition, he held executive roles at a variety of healthcare companies, where he was the driving force behind global product education teams and programs. Widely known for his education and training expertise, he has conducted Art of the Healthcare presentation training for the University of Miami Osher Center, Cleveland Clinic Center for Functional Medicine, Duke Integrative Medicine, and the Academy of Integrative Health & Medicine.

We are honored to welcome Dr. Tager, one of the most renowned experts in integrative wellness to our Scientific Advisory Board, said Scott Sensenbrenner, President & CEO of Enzymedica. We believe Dr. Tagers unparalleled expertise in integrated health and education will be a tremendous asset as Enzymedica continues to be a pioneer in the natural products industry by creating new learning platforms that are both innovative and revolutionary.

Enzymedica is addressing a large unmet need by delivering accuracy and accessibility in education to consumers, retailers, and healthcare professionals, Dr. Tager commented. I am pleased to join Enzymedicas Scientific Advisory Board and look forward to collaborating with other top industry experts as we work together to advance education in the natural products industry.

About EnzymedicaEnzymedica is a Florida-based, natural digestive health company since 1998 that sells to over 30,000 stores worldwide and online. Its top-selling enzyme brand is No. 1 in America. In addition to high quality products, Enzymedica also is dedicated to its People & Planet initiative, which is a core pillar within the companys mission - to leave a legacy that will make the world a better place. The company has received more than 50 industry awards including multiple Better Nutrition Magazines People's Choice Awards, many Best of Supplements Awards and numerous VITY and Nexty Awards. Visit https://enzymedica.com/ for more information.

Media ContactRia RomanoRPR Public Relations, Inc.Tel. 786-290-6413

Share article on social media or email:

Read more here:
Enzymedica Announces Newly Formed Scientific Advisory Board and the Appointment of Renowned Integrative Wellness Expert Dr. Mark Tager as a Key Member...

United States Health Coaching Market Report 2021-2025 with Discussion of Effects of the COVID-19 Pandemic on Operations/Growth – PRNewswire

DUBLIN, Jan. 18, 2021 /PRNewswire/ -- The "The U.S. Health Coaching Market" report has been added to ResearchAndMarkets.com's offering.

Health coaching has emerged as a $7 billion service market, with a strong growth outlook.

An estimated 128,000 health coaches and health educators advise and motivate clients to change bad lifestyle habits and to manage chronic conditions such as diabetes. Consumers, employers and insurers are each now more seriously focused on improving health and being proactive, in light of the pandemic, rising obesity levels, and chronic health conditions.

You are most likely to find a health coach in private practice, at a healthcare insurer, or via a corporate wellness program. Large self-insured companies are using coaches to improve employee health and cut claims costs, as are healthcare insurers. However, like coaching in general, the industry is loosely defined and certification in many cases is performed by many competing organizations. However, national standards have been developed and CPT billing codes and reimbursement are on the near-term horizon.

This new report covers the following: market definition - types of health coaches, what they do, where they work, their number, annual salaries, market structure, market size: 2006-2025 forecast, effects of the Covid-19 pandemic, profiles of the 8 major certification organizations, profiles of insurance company users (Aetna, Cigna, Humana, United Health Group), MD and Veterans Administration programs, demand factors and usage by consumers, findings of telephone interviews with key market influencers, list of the top health coaching apps, and the industry's major issues, obstacles and growth drivers. Includes list of 75 approved certification training programs.

Key Topics Covered:

Introduction: Study Scope & Methodology

Market Definition and Summary

Market Status Report

Market Size & Growth

Tables:

Profiles of leading Health Coach Certification & Training Organizations (Descriptions of organizations and their certification programs)

Consumer Demand Factors & Outcome Studies

Large Healthcare Organizations' Usage of Health Coaches

List of Most Popular Health Coaching Apps

Reference Directory

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/6w3pso

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Continue reading here:
United States Health Coaching Market Report 2021-2025 with Discussion of Effects of the COVID-19 Pandemic on Operations/Growth - PRNewswire

How do we treat the now uncommon cold? – Galveston County Daily News

The art of medicine consists of amusing the patient while nature cures the disease. Voltaire

These days, every sniffle, cough or sneeze makes us and everyone around us jumpy that we might be carrying COVID. Yes, colds, flu and allergy symptoms are still with us, though at a reduced rate because of isolation, masking, hand-washing and the rest. The pediatric wards are nearly empty, with major decreases in the usual respiratory infection surges seen this time of year with children largely out of school.

Colds, flu and allergy are each a different upper respiratory entity and may be difficult to tell from COVID or even each other. Flu, compared to the cold usually is more intense; I call it the run over by a truck syndrome, though getting the flu vaccine can decrease symptoms significantly.

As north winds bring us the gift of pollens from the mainland, winter allergies develop causing sneezing, coughing, itchy eyes, clear nasal discharge and earaches.

Colds dont generally start with the high fever, fatigue, sore throat, shortness of breath, low oxygen levels seen in COVID, though a bad flu can look and feel more like moderate to severe COVID.

When in doubt, call your health care professional or go in for a COVID and/or flu test. Get your COVID vaccine as soon as you can.

The common cold is actually related to the coronavirus. It has been around for a long time without such serious harm. And it brings its own brand of misery, runny nose, cough, low-grade fever, headache and other familiar symptoms. School and work absences result.

As a primary care doctor and student of home and folk remedies, Ive learned that treating colds is more a matter of art and tradition than science. I observe, for example, that many folks seem to come down with a cold after a particularly stressful period in their lives.

The National Institutes of Healths National Center for Complementary and Integrative Medicine just reviewed research literature on alternative and over-the-counter treatments for the common cold. Check it out at: http://www.nccih.nih.gov/health/providers/digest/the-common-cold-and-complementary-health-approaches?nav=govd

Among these were zinc, vitamin C and nasal saline rinses ranking best in safety and efficacy. However, as with elderberry, probiotics, honey, garlic and geranium extract, the research to support most of these remedies was generally weak. Plus, antibiotics dont work for colds.

People still have used such remedies in their own cultures and homes for centuries. They just want to do something to feel better, benefitting from the placebo effect and tincture of time for relief. Or just maybe some remedies actually do work, having stood the test of time.

Adequate rest is hugely important in supporting our immunity. Keeping well hydrated prevents mucosal membranes from drying out and thus losing their protective barriers. Nasal irrigation is helpful to remove not only mucus but inflammatory chemicals. Hot soups and steam inhalation or vaporizers help.

So, be sensible and cautious this winter, and use the best ideas that science and grandma have to offer.

Dr. Victor S. Sierpina is the WD and Laura Nell Nicholson Family Professor of Integrative Medicine and Professor of Family Medicine at UTMB.

See the article here:
How do we treat the now uncommon cold? - Galveston County Daily News

The Golden Ingredient Of Ayurveda: A Complete Guide To Turmeric & The Skin – mindbodygreen.com

As always with any new product or DIY experiment, do a patch test before slathering on; just because you can consume the spice doesn't mean your skin will tolerate it the same way. Sometimes people can have unexpected reactions to the topical treatment, especially if you have sensitive skin.

Finally, we'd be remiss not to discuss traditional turmeric's bright orange hue, which makes for a beautiful mask, sure, but turmeric is also notorious for staining (your clothes and your skin, it turns out). To avoid tinging your face orange, using just a small amount of the spice in your DIY adventures. Or, you can find the aforementioned kasturi turmeric and avoid this problem altogether.

And the worst case scenario: The staining only temporary. So don't freak! "Curcumin, the main component of turmeric, is oil-soluble," says Plescia. So a gentle oil cleanser should be able to remove the pigment, even if it does take a couple of times for it to totally clear. Even if you leave the stain alone completely, the sebum in your skin will lift off the pigment eventually.

As for ingesting the spice, if you take too much curcumin, it can cause bleeding and bruising, says Yufang Lin, M.D., an integrative medicine specialist at Cleveland Clinic. So stick to the typical dosing, which is usually around 500 milligrams max per day. "Allergic reaction and intolerancesuch as stomach upset, diarrhea, and refluxare possible," Lin adds, but this is extremely rare.

View original post here:
The Golden Ingredient Of Ayurveda: A Complete Guide To Turmeric & The Skin - mindbodygreen.com

Letters: our children are in crisis and need help – The Guardian

The pandemic is having a devastating effect on the childhoods of children and young people across the country. Growing numbers of hard-pressed families are being swept into poverty, with more than 4 million children living in poverty even before Covid wrecked the economy. The closure of schools has widened the yawning education gap and the spiralling numbers of young people suffering mental illness and psychological distress look certain to increase with every day that lockdown keeps them isolated and uncertain about their futures.

These challenges are taking place just as the local services that children and their families rely on to keep them safe are reeling from the combined effect of more than 2bn in funding cuts over the last 10 years, coupled with unprecedented demand for their help.

Childrens welfare has become a national emergency. An independent commission, to inform a cross-government strategy to steer children and young people clear from the lingering effects of Covid-19, could avert this. This commission should bring together representatives from across the sector, including charities, school leaders, teaching unions, education experts, doctors and mental health professionals, as well as the childrens commissioner.

A strategy to protect children from the worst effects of the pandemic should build on the principles for recovery set out by leading childrens charities and must involve children, young people and parents in creating a vision for their futures. At present, we have piecemeal solutions and stopgap measures. The next generation deserves better.Anna Feuchtwang, CEO, National Childrens Bureau and chair, End Child Poverty; Cathy Creswell, professor of developmental clinical psychology, University of Oxford; Jo Revill, CEO, Royal College of Paediatrics and Child Health; Melanie Armstrong, chief executive, Action for Children; Dr Marian Davis, GP and chair of the Adolescent Health Group at Royal College of General Practitioners; Kathy Evans, CEO, Children England; Emma Thomas, chief executive, YoungMinds; Peter Grigg, CEO, Home-Start UK; Mark Russell, CEO, The Childrens Society; Katharine Sacks-Jones, chief executive, Become; Joseph Howes, CEO, Buttle UK; Thomas Lawson, chief executive, Turn2Us; Niall Cooper, director, Church Action on Poverty; Dr Wanda Wyporska, executive director, The Equality Trust; Dr Lee Hudson, clinical associate professor, Great Ormond Street UCL Institute of Child Health; Leigh Middleton, CEO, National Youth Agency; Dr Marian Davis, GP and chair of the Adolescent Health Group at Royal College of General Practitioners; Dr Ronny Cheung, consultant paediatrician and clinical lead for State of Child Health programme, Royal College of Paediatrics & Child Health; Dr Carol Homden, CEO, Coram Group; Essi Viding, professor of developmental psychopathology and co-director of Developmental Risk and Resilience Unit, division of Psychology and Language Sciences, University College London; professor Pasco Fearon, chair of Developmental Psychopathology, research department of Clinical, Educational and Health Psychology, University College London; Paul Bywaters, professor of social work, University of Huddersfield; Sarah-Jayne Blakemore, professor of psychology and cognitive neuroscience, University of Cambridge; Frances Mapstone, interim CEO, Just for Kids Law; Louise King, director, Childrens Rights Alliance for England; Dr Damian Roland, honorary associate professor in paediatric emergency medicine, Leicester University; Ann John, professor of public health and psychiatry, Swansea University, lead of the Adolescent Mental Health Data Platform; Helen Dodd, professor of child psychology, University of Reading; Tamsin Ford, professor of child and adolescent psychiatry, University of Cambridge; Dr Bonamy Oliver, associate professor in developmental psychology, UCL Institute of Education; Thalia Eley, professor of developmental behavioural genetics, Institute of Psychiatry, Psychology & Neuroscience, Kings College London; Sally McManus, senior lecturer, School of Health Sciences, City University of London; Robin Banerjee, head of the school of pPsychology and professor of developmental pPsychology, University of Sussex; Sarah Halligan, professor of child and family mental health, University of Bath; Siobhan ONeill, professor of Mental Health Sciences, Ulster University and interim mental health champion for Northern Ireland; Sam Cartwright-Hatton, professor of Clinical Child Psychology, University of Sussex; Dr Kathrin Cohen Kadosh, reader developmental cCognitive neuroscience, University of Surrey; Dr Nick Owen, CEO, The Mighty Creatives; Laura Payne, campaign manager, 4in10 Londons Child Poverty Network; Willem Kuyken, Ritblat professor of mindfulness and psychological Science, University of Oxford; Angelica Ronald, professor of Psychology and Genetics and joint editor of Journal of Child Psychology and Psychiatry, University of London; Dr Maria Loades, child and adolescent clinical psychologist and senior lecturer in clinical pychology and NIHR researchfellow, University of Bath; Sarah Hughes, CEO, Centre for Mental Health; Sir Norman Lamb, chair, Children & Young Peoples Mental Health Coalition; Claire Donovan, campaigns manager, End Furniture Poverty; Jane Streather, chair, North East Child Poverty Commission; Monica Holton, CEO, The Loveinspire Foundation; Irene Audain, chief executive, Scottish Out of School Care Network; Andrew Copson, chief executive, Humanists UK; Julie Anderson, professor of modern history, University of Kent; Laurence Guinness, chief executive, The Childhood Trust; David Holmes, CEO Family Action; Becca Lyon, head of Child Poverty, Save the Children UK; Dr Robbie Duschinsky, head of the Applied Social Sciences Group, Primary Care Unit, University of Cambridge; June OSullivan, CEO London Early Years Foundation; Purnima Tanuku, chief executive, National Day Nurseries Association; Dr Xand van Tulleken, presenter of Operation Ouch; James Matheson, GP and chair of the Health Inequalities Group, Royal College of GPs; Alison Garnham, CEO, Child Poverty Action Group; Dr Elvira Prez Vallejos, associate professor Mental Health and Technology, the University of Nottingham; The British Psychological Society

How I enjoyed reading the excerpt from the late, lamented Katharine Whitehorns Sluts column, even though I still have the original safely stashed away somewhere in my muddle of memorabilia (Thank you, Katharine Whitehorn, for giving all the female reprobates a voice, Comment). The references to black stockings and white gloves were poignant. As a young fashion editor myself, in awe of the Katharine I would spot at fashion shows, it was always white gloves that famous photographic models (who would get out of bed for a mere three guineas an hour in those days) were required to bring on fashion shoots.

Happy memories of a bygone age, beautifully chronicled in your pages over the years by a brilliant writer whose words, I hope, will be savoured by generations to come.Jenny FroudeBeckenham, Kent

Andrew Rawnsley writes: Mr Trump has done far more damage to trust in Americas system of government than Vladimir Putins battalions of cyber-agents ever managed (Tyrants gaze with glee at what Trump has done to American democracy, Comment). However, it is questionable whether Trump would ever have been in a position to wreak such havoc without Russian interference in the 2016 US presidential election.Robert SaundersBalcombe, West Sussex

I wish I could share Will Huttons optimism about I ending and we returning (The only way to vanquish the pandemic is for the age of national self-interest to end, Comment). But I fear the age of I is too hard-baked into the DNA of too many. It will take a generation at least to dissolve it.

I speak from experience, having been part of the yuppie generation spawned and nurtured during the Thatcher era. I look back in shame and disbelief at how great swaths of us behaved. How possessions were accumulated with little reason other than the desire to show ones wealth and status.

This government actively encourages the I society. Weve had a brief glimpse of the we returning but it requires more than a handclap for our NHS. This is where Sir Keir Starmer and Sir Ed Davey need to pool their resources. Theres a world of we supporters waiting for leadership.Michael NewmanShefford, Bedfordshire

Philip Oltermanns article on integrative treatment of Covid-19 in German hospitals is biased against anthroposophic medicine but rightly highlights how complementary treatments are provided in addition to state-of-the-art conventional treatments, including for critically ill patients in the intensive care ward (Ginger root and meteorite dust: thats what Covid patients can expect in Rudolf Steiner clinics, World). Anthroposophic medicine is fully integrated into the German healthcare system in line with the World Health Organizations traditional medicine strategy that has set integration of traditional and complementary medicine into healthcare systems as a strategic goal.

There are many peer-reviewed studies on anthroposophic medicine and anthroposophic medications have been in use for decades, with an excellent safety record. Mr Oltermanns critique that patients should provide consent for such treatments does not hold because the treatments are not experimental and are provided in addition to standard care, based on long clinical experience and in hospitals openly publicising their integrative medicine approach. As the article reports, German insurance companies pay flat-rate payments for hospital treatment of coronavirus patients; the additional anthroposophic treatments are financed out of hospital budgets.

Mr Oltermann links anthroposophic medicine with those who are anti-vaccination. While this might be true for certain individuals, a recent statement by the International Federation of Anthroposophic Medical Association (IVAA) welcomes the Sars-CoV2 vaccines and supports their rollout worldwide.Thomas Breitkreuz and Tido von Schoen-Angerer, president and vice-president of the International Federation of Anthroposophic Medical AssociationsBrussels

The publishing project that draws attention to hitherto neglected black writers, led by the author Bernardine Evaristo, is to be applauded (The lost novels of black Britain: Booker winners mission to put forgotten writers back in print, News).

An almost forgotten black writer of great literary merit is George Lamming. He came to Britain in 1950 from the West Indies when he was 23. His first novel, In the Castle of My Skin, won the Somerset Maugham award for literature in 1957. Perhaps his most challenging and appropriate work for our post-colonial times was Natives of My Person. Lamming went on to have a fine academic career in the US and the West Indies, as well as publishing several other acclaimed works. He deserves greater recognition.Peter BunyanBillericay, Essex

Read more from the original source:
Letters: our children are in crisis and need help - The Guardian

Rutland Integrative health: Winter survival guide | Weekend Magazine | rutlandherald.com – Rutland Herald

It is a new year, a collective sigh of relief to be moving on, yet we are still very close to the winter solstice, the deepest darkest day of winter. In 2020, we all experienced a massive slow down, halting social gatherings and various hobbies or activities. For many, like me, this has been difficult on the psyche, challenging our beliefs about what forward momentum and success looks like. We live in a society that congratulates us for doing more and pushing harder; it is the measure of who we are, or is it?

In eastern traditions, winter is the time of the year that is the most yin, we call it yin within yin. Yin is likened to darkness, quiet, night, rest, regeneration and stillness. It is the time when we restore, when our body does its deepest healing and regenerating. We are at the most opportune time of year to conserve energy and slow down. Overdoing during this time of year can be counterproductive and actually cause the release of the stress hormone cortisol. By honoring the winter season annually, it sets us up for a more successful year mentally and physically. This is the time of year that sets the stage for the other seasons to follow: the spring when we want to move, plant a garden and have extra energy for new projects, the summer when we have long days, tend the garden and often sleep less, as well as the fall with the continued momentum from the year, the harvest and finishing up of various projects.

This is the time of year when best practices include the following:

Get more sleep. Deep sound sleep is restorative and feels amazing but can sometimes be illusive. Sleep could also mean a nap or a rest in the middle of the day.

Consider your movement. Just because its winter and maybe we feel less motivated to exercise doesnt mean we shouldnt. This is a time when slower, more fluid movement is vital to lubricate the joints, stretch the connective tissue, allow for proper circulation throughout the cardiovascular and lymphatic systems.

Habits that restore and replenish are important as we have become so deeply embedded in electronic entertainment. Finding things to do that truly invoke cellular restoration provide a formidable response that can be felt within. Some suggestions include: epsom salts bath, reading a book, meditation, get out in nature, journaling, breath work, gratitude practice, drink a cup of tea, take a nap.

Hydration: Almost everyone can drink more water. Especially if you are noticing that your skin is dry, your hands or feet or your lips are cracked, this means you are dehydrated. We should each be getting approximately half of our bodys weight in ounces daily. If you are having any caffeine or alcohol, or if you are sweating more than a little, you will need even more water daily. Its best to drink water earlier in the day, which is not a habit many of us are into; however, it ensures the daily intake is more, and we are not up in the night too often. Starting your day with a large warm glass of lemon water, you can add cinnamon or ginger for an even more warming drink, aids in eliminating toxins, ensures daily bowel flow and sparks our metabolic fire.

Food therapy: Choose foods that grow naturally during the winter. Items such as squash, potatoes, pumpkin, sweet potatoes, cinnamon, nutmeg, cardamom, root vegetables such as beets, greens, carrots, mushrooms, apples, pears and cabbage, are great. During the winter months, cold foods like salads and raw foods should be avoided as they can deplete the immune system because their thick cellulose wall causes them to be difficult to digest. There are foods that specifically target and nourish the organ system in eastern medicine that is working the hardest for us during this time of year the kidneys. These foods include kidney and black beans, beef, goose, duck, lamb, chicken, dark leafy greens, garlic, ginger, walnuts, quinoa, asparagus, celery, onion, fennel, scallions, cloves, watercress and turnips.

Stay warm: Keeping our skin specifically, feet, hands, head and lower back covered and warm this time of year increases our bodys ability to fight off viral infections and supports the balance of flexibility versus contraction in the musculature. This allows for ease of physical movement in the spring and summer months.

Creating healthy habits this time of year will support you as the seasons progress. By honoring the current season and your body, you are enabling innate healing to occur.

Dalite Sancic, DAOM, L.Ac, MS, is a doctor of East Asian Medicine at Rutland Integrative Health.

See the original post:
Rutland Integrative health: Winter survival guide | Weekend Magazine | rutlandherald.com - Rutland Herald

Make ‘Go on a Diet’ Resolutions Obsolete With The Whole Person Integrative Eating Program – Van Nuys News Press

NEW YORK, NY What if you never again need to make a New Years resolution to lose weight or go on a diet because your most-of-the-time way of eating empowers you to eat and weigh less? Original, pioneering research by holistic nutrition researcher Deborah Kesten, M.P.H., and behavioral scientist Larry Scherwitz, Ph.D.authors of the award-winningWhole Person Integrative Eating: A BreakthroughDietary Lifestyleto Treat the Root Causes of Overeating, Overweight, and Obesityreveals that replacing the complex reasons you overeat calledovereatingstyleswith the scientifically sound Whole Person Integrative Eating (WPIE)dietary lifestyle(meaning, WPIE is a way of life; its not a traditional diet) may make weight-loss resolutions obsolete.

Now is the time to reset and rethink what and how we eat; to replace traditional dieting with a scientifically sound way of eating thatlessens overeatingand that leads naturally to weight loss, health and healing, says Kesten.

Kesten and Scherwitz share a simple yet powerful premise: Identify the reasons you overeat (your overeating styles) and gain weightwith the illuminating self-assessment quizthen overcome overeating and lose weight by replacing your overeating styles with the antidotes: the elements of the Whole Person Integrative Eating program.

By shedding light on the root causes of overeating, Kesten and Scherwitz present a program that empowers readers with a personalized plan, and in turn new hope and new choices to help them reduce overeating, lose weight and keep it off.

WPIE isnota diet that a person goes on then off. It is a scientifically sounddietary lifestyledesigned to be practiced for a lifetime.

If people follow the revolutionary program outlined in this game-changing, insightful book, it may be the most helpful step they can take toward losing weight and keeping it off, says bestselling author Kenneth Pelletier, M.D., Ph.D., clinical professor of medicine at University of California School of Medicine, San Francisco.

The authors paradigm-shifting message is that food influences not only the physical dimensions of health, but also our emotional, spiritual and social well-being. Their dietary lifestyle can build bridges between the millions who struggle with overeating and weight issues and the medical community. And it can inspire us all to re-envision our relationships with food, eating and weight, so that each time we eat, we are nourished for life.

Deborah Kesten, M.P.H.,is an international nutrition researcher, award-winning author and health journalist, with a specialty in preventing and reversing obesity and heart disease.She is also an experienced, expert speaker and presenterfrom TV and podcast interviews to large conferences and small-group workshops.

Kesten served as Nutritionist on Dean Ornish, M.D.s first clinical trial for reversing heart disease through lifestyle changes, the results of which were published in theJournal of the American Medical Association. She was Director of Nutrition at cardiovascular clinics in Europe and on the Board of Directors of the American Heart Association, San Francisco.

Kesten has published more than 400 nutrition and health articles. Her first book,Feeding the Body, Nourishing the Soul, received the first-place gold award in the Spirituality category from the Independent Publisher Book Awards.Whole Person Integrative Eatinghas been honored with the No.1 gold, best-book award in the Health category by Book Excellence Awards and is a No. 1 Amazon best seller. Kesten is a VIP Contributor at Arianna Huffingtons Thrive Global, and is married to behavioral scientist and co-author ofWhole Person Integrative Eating,Larry Scherwitz, Ph.D.

For more information, please visitwww.IntegrativeEating.com. You can also connect with the author on the following social media sites:https://www.instagram.com/integrativeeating/;

https://www.facebook.com/WholePersonIntegrativeEating;https://twitter.com/IntegrativeEat1.

Short URL: http://www.vannuysnewspress.com/?p=37986

See the original post here:
Make 'Go on a Diet' Resolutions Obsolete With The Whole Person Integrative Eating Program - Van Nuys News Press

Five Fantasies That Keep Us Apart – Laredo Morning Times

Deepak Chopra, Special to SFGate

When a society is deeply divided, a paradox is in force. On the one hand, people cry out for unity, while on the other hand, they keep on doing the very things that incite division. We are seeing this paradox grow stronger year by year in politics, but at bottom what were facing is a broken relationship. Society is a huge bundle of relationships, nothing more.

To stop being trapped in a paradox, you need a little practical psychology. The first step when a relationship falters, if you consider the situation psychologically, is to stop doing more of what didnt work in the first place. The same holds true in a divided society.

As long as both sides engage in futile behavior, ending the divide between them isnt going to happen. At a certain point a futile tactic turns into a fantasy. Here Id define fantasy as a belief that runs contrary to reality. If you confront the realities of a situation but continue to ignore them, you are indulging in a fantasy.

Here are five fantasies that surround us right now. Ill couch them in terms of a broken relationship.

Fantasy No. 1: You need to listen to me. Meanwhile, I refuse to listen to you.

When two opposing sides stop listening to each other, the relationship has reached an impasse. Communication has shut down. In its place, rigid rituals are acted out. These rituals consist of repeating the same argument over and over, shouting to try and be heard, and freezing the other side out with rude contempt or silence.

Fantasy No. 2: Everything will be okay if you change. I certainly dont need to change.

This is the classic disguise for blame. When you demand that the other person change, you are judging against them without really coming out and saying so. What fuels this fantasy is the delusion that others change if you blame them enough. The other part of the fantasy is a self-righteous confidence that you dont need to change because the other person has no right to blame you.

Fantasy No. 3: You are here to make me happy. Until you do that, I cant relate to you.

This fantasy is a holdover from childhood. Young children pout and cry when they are unhappy, and as long as they are unhappy, they dont relate. They are too sunk in their own feelings. When carried over into adulthood, however, the same attitude becomes narcissistic. No one outside your marriage or intimate partnership is here to make you happy. To cut off ties because you are waiting to be made happy leads nowhere if your aim is to bring people together.

Fantasy No. 4: Im better than you. Thats why I have the right to tell you what to do.

Much of social discord can be laid down to a mutual superiority complex. Tune in to commentators for the other side, and you will probably be shocked at their sense of superiority, especially if you think that only your side has the right to feel superior. In reality, neither side has the right to feel superior. If this fact is ignored, there is no chance for reconciliation.

Fantasy No. 5: I deserve to win, and once I do, you will be sunk once and for all.

This is the emotional equivalent of a zero-sum game. The Super Bowl is a zero-sum game because only one side can win. But human affairs are tidal. One day you are down, the next day you are up. The belief that you can be up forever and never down again is pure fantasy.

If two people, two factions or two nations find themselves stuck at an angry impasse, these five fantasies are almost always in play. Perhaps not all of them at once, and perhaps not everyone is honest about how they feel, yet this makes no difference. Each fantasy is based on two underlying tendencies. The first tendency is holding judgments; the second tendency is us-versus-them thinking. Each fantasy expresses these two tendencies in a slightly different way. But you can be sure that they are present.

Calls for unity, comity, and healing dont lead to actual healing until both sides stop engaging in more of what never worked in the first place. By looking closely at how we indulge in fantasy, we can get much closer to turning good intentions into reality.

DEEPAK CHOPRA MD, FACP, founder of The Chopra Foundation, a non-profit entity for research on well-being and humanitarianism, and Chopra Global, a whole health company at the intersection of science and spirituality, is a world-renowned pioneer in integrative medicine and personal transformation. Chopra is a Clinical Professor of Family Medicine and Public Health at the University of California, San Diego and serves as a senior scientist with Gallup Organization. He is the author of over 90 books translated into over forty-three languages, including numerous New York Times bestsellers. His 90th book and national bestseller, Metahuman: Unleashing Your Infinite Potential (Harmony Books), unlocks the secrets to moving beyond our present limitations to access a field of infinite possibilities. For the last thirty years, Chopra has been at the forefront of the meditation revolution and his latest book, Total Meditation (Harmony Books, September 22, 2020) will help to achieve new dimensions of stress-free living and joyful living. TIME magazine has described Dr. Chopra as one of the top 100 heroes and icons of the century. http://www.deepakchopra.com

Read more from the original source:
Five Fantasies That Keep Us Apart - Laredo Morning Times

To Be Healthier, Boost Immunity, Reduce Pain, Just Go Plant-Based – The Beet

Feeling young is great, but acting like an adult means taking care of your health

Mentally, 73 percent of Americans feel younger than they really are. So while they are feeling oldphysically they are young at heart, but perhaps this youthful spirit could be misleading them to believe they can eat and drink as they did in high school. It's time to change our diets to reverse the clock, not replicate our happy days.

The top struggle of growing up is being responsible for their physical health, 4 in 10 people said, including making their own doctors appointments.The same proportion of respondents admitted to not buying nutritious food when grocery shopping.

Sixty-three percent of respondents say they feel much older than they expected to at their current age.

The survey data reveals that nutrition gaps are more than common among adults in this age group, but thats not necessarily a surprise. For example, its understandable that busy adults dont necessarily have time to cook the recommended servings of fish per week, even though it is an excellent source of Omega-3s that support heart and immune health, said Dr. Taz Bhatia, Integrative Medicine Physician. (Note that the Mediterranean Diet includes fish while a plant-based diet gets Omega-3s from algae and plant-based sources.)

If you cant add more of these foods to your diet, one of the best ways to mitigate these nutrient gaps is with high-quality supplements, she added. Look at how the supplements are sourced, the quality and quantity of the ingredients, and any third-party testing.Sixty-three percent of respondents said that as theyve gotten older, the number of vitamins and supplements they take has increased. However, two-thirds still feel like they should be taking more than they currently do.

The biggest challenges ofbecomingan adult, according to the survey

Continued here:
To Be Healthier, Boost Immunity, Reduce Pain, Just Go Plant-Based - The Beet

Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis -…

SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, Clene) today announced that its wholly-owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, was issued a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its invention for using its patented clean-surfaced gold nanocrystals for treating patients with multiple sclerosis (MS).

Clene notes that its previously patented gold nanocrystals have surfaces that are substantially free from organic impurities and are therefore clean relative to surfaces of gold nanoparticles made by other processes. The allowed application discloses that these gold nanocrystals can be suspended in water and can be taken orally, for example, by a person with MS.

As the leading developer of clean surfaced nanocrystal therapeutics for humans, we continue to expand our patent estate and are pleased to receive this latest Notice of Allowance from the USPTO. While the only approved treatments for MS today are immunomodulators, we see an opportunity to treat MS through a completely different mechanism of action utilizing the therapeutic bioenergetic effects of catalytic gold nanocrystals, such as CNM-Au8. This Notice of Allowance comes as we are conducting two Phase 2 studies of our lead drug candidate CNM-Au8 in the treatment of MS, stated Rob Etherington, President and CEO of Clene.

MS affects anestimated 1 million people in the U.S. and 2.5 million worldwide, with a treatment market valued at $23 billionglobally.

New data is expected from Clenes REPAIR-MS Phase 2 study of CNM-Au8 in the second half of 2021. Prior interim results from this study showed CNM-Au8 was associated with improvements across key central nervous system (CNS) bioenergetic metabolites.

Clenes VISIONARY-MS Phase 2 study is evaluating the efficacy and safety of CNM-Au8 as a remyelinating and neuro-reparative treatment in stable relapsing MS patients with chronic visual impairment. Interim data from the Phase 2 VISIONARY-MS trial demonstrated notable, exposure-related median improvements in the primary endpoint. Completion of enrollment is expected by the end of 2021.

Clenes worldwide patent portfolio in the new field of clean-surfaced nanocrystal therapeutics includes over 100 patents issued and allowed, with around 30 more pending. The issued patents cover state of matter claims for suspensions and solutions, as well as processes for making the materials, devices for conducting the unique electro-crystal chemistry processes, and methods of using the novel materials, such as in this instance of using clean-surfaced gold nanocrystals for treating patients with MS.

About CNM-Au8

CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, MS and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS, in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.

About Clene

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Clene's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant known and unknown risks and uncertainties, many of which are beyond Clenes control and could cause actual results to differ materially and adversely from expected results. Factors that may cause such differences include Clenes ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Clenes ability to achieve commercial success for its marketed products and drug candidates, if approved; Clenes ability to obtain and maintain protection of intellectual property for its technology and drugs; Clenes reliance on third parties to conduct drug development, manufacturing and other services; Clenes limited operating history and its ability to obtain additional funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on Clenes clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled Risk Factors in Clenes recently filed registration statement on Form S-4, as well as discussions of potential risks, uncertainties, and other important factors in Clenes subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media ContactAndrew MielachLifeSci Communications(646) 876-5868amielach@lifescicomms.com

Investor ContactBruce MackleLifeSci Advisors, LLC(929) 469-3859bmackle@lifesciadvisors.com

Source: Clene Inc.

Continued here:
Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis -...

Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis – DocWire News

This article was originally published here

Molecules. 2021 Jan 13;26(2):E384. doi: 10.3390/molecules26020384.

ABSTRACT

Patients with advanced prostate cancer can develop painful and debilitating bone metastases. Currently available interventions for prostate cancer bone metastases, including chemotherapy, bisphosphonates, and radiopharmaceuticals, are only palliative. They can relieve pain, reduce complications (e.g., bone fractures), and improve quality of life, but they do not significantly improve survival times. Therefore, additional strategies to enhance the diagnosis and treatment of prostate cancer bone metastases are needed. Nanotechnology is a versatile platform that has been used to increase the specificity and therapeutic efficacy of various treatments for prostate cancer bone metastases. In this review, we summarize preclinical research that utilizes nanotechnology to develop novel diagnostic imaging tools, translational models, and therapies to combat prostate cancer bone metastases.

PMID:33450939 | DOI:10.3390/molecules26020384

Go here to read the rest:
Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis - DocWire News

NanoView Biosciences Strengthens Executive Team – BioSpace

BOSTON, Jan. 13, 2021 /PRNewswire/ -- NanoView Biosciences, Inc., the leader in single exosome characterization, today announced the expansion of its management team with the appointment of David Hanlon, Ph.D. to the position of Vice President, Strategic Collaborations. The addition is a key part of the company's strategy to create and expand strategic partnerships within the life sciences, pharmaceutical and diagnostics markets.

Dr. Hanlon brings over 20 years of product development and commercialization experience to NanoView, most recently serving as Vice President of Strategic Collaborations at Quanterix. Over the last 12 years he has led the strategic marketing efforts and established an assay service laboratory to support new applications and drive commercial interest. He has held leadership roles in several life sciences and diagnostics companies, including Hologic (formerly Cytyc), where he directed multiple biomarker programs to develop diagnostic tests for cervical cancer. Dr. Hanlon received his Ph.D. in Biochemistry from the University of Illinois, Urbana-Champaign and B.S. from Worcester Polytechnic Institute.

"We are very excited to welcome David Hanlon to NanoView as we enter a significant growth phase for the Company," said Jerry Williamson, CEO of NanoView Biosciences. "His expertise in establishing and expanding strategic relationships for life science technology providers will accelerate the success of NanoView and we look forward to his contribution on our executive team."

Commenting on his new role, Dr. Hanlon added, "I am very excited to be joining NanoView, a ground-breaking organization that has developed a novel platform solution to characterize extracellular vesicles in human disease. I look forward to working with the leadership team as the organization continues to expand its product and service offerings to help researchers and clinicians leverage the potential of exosomes in this era of personalized medicine."

NanoView has created ExoView, a unique and proprietaryplatform which provides high-resolution sizing, counting and phenotyping of exosomes and viral vectors at the single vesicle level. Understanding the molecules carried by extracellular vesicles has potential for diagnostic, prognostic, and therapeutic use for a broad range of diseases. ExoView requires low sample input, no extensive sample preparation or purification, and minimal hands-on time. It can be used directly with complex biological samples.

The ExoView platform is designed For Research Use Only. It is not for use in diagnostic procedures.

About NanoView Biosciences

NanoView Biosciences, a Boston-based, privately-held company, is focused on enabling worldwide life science researchers to better understand the biological role of extracellular vesicles, including exosomes and viral vectors, and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease. The Company's proprietary product, the ExoView platform, was designed to fully characterize exosomes and other extracellular vesicles for use in research and in the implementation of precision nanomedicine. ExoView is a high-throughput, cost-effective analysis platform that is easy to use and does not require purification or large sample volumes to accurately analyze exosomes.

http://www.nanoviewbio.com

View original content:http://www.prnewswire.com/news-releases/nanoview-biosciences-strengthens-executive-team-301207135.html

SOURCE NanoView Biosciences

See the rest here:
NanoView Biosciences Strengthens Executive Team - BioSpace

Amyotrophic Lateral Sclerosis Market Anticipates Sizeable Growth at a CAGR of 28% during the forecast period (2020-2030) with the US expected to top…

LAS VEGAS, Jan. 18, 2021 /PRNewswire/ -- The surge in the Amyotrophic Lateral Sclerosis (ALS) market can be attributed to a vast pipeline, initiation of HEALEY ALS platform trials, mutation-specific treatment development in the pipeline, a need for a curative treatment option, increase in the ALS prevalence, effective drug approvals in the past 3-4 years, improvisations in market regulatory guidelines, growing awareness about the disease, along with geographical expansions and meaningful collaborations in the ALS pharma industry.

Amyotrophic Lateral Sclerosis Marketreport offers detailed coverage of the disease, its available treatment options, patient pool, and diagnostic modalities. The report lays down the comprehensive insights into market outlook, upcoming pipeline therapies, and unmet needs along with the major collaboration and funding opportunities in the ALS market landscape.

Some of the highlights of the Amyotrophic Lateral Sclerosis marketreport:

Know more about the report highlights @Amyotrophic Lateral Sclerosis Market Landscape and Forecast

Amyotrophic Lateral Sclerosis, commonly known as Lou Gehrig's disease, is a group of progressive, rare neurological diseases, which are a result of gradual deterioration and death of motor neurons. Over time the muscles weaken, start to twitch (called fasciculations), and waste away (atrophy), eventually, leading the brain to lose its ability to initiate and control voluntary movement.

ALS can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. On the basis of mutation, ALS patients can exhibit mutations such as C9ORF72, SOD1, along with others including TARDBP, FUS, OPTN, ANG, etc., and non-mutated/unidentified mutations. The diagnosed Amyotrophic Lateral Sclerosis prevalent cases in the 7MM are estimated to be 48,112 in 2020, which is further expected to increase by 2030.

The Amyotrophic lateral sclerosis epidemiology section of the report proffers insights into the historical and current Amyotrophic lateral sclerosis (ALS) patient pool and forecasted trends for 7MM. ALS report provides historical as well as forecasted epidemiology segmentation for the study period 2017-30:

Visit, Amyotrophic Lateral Sclerosis Epidemiology, for more information

Amyotrophic Lateral Sclerosis Therapeutic Market Landscape

The Amyotrophic Lateral Sclerosis treatment landscape includes multidisciplinary care, such as physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy and others. Approved drugs in the ALS market comprises Riluzole, Nuedexta, Radicava, and Tiglutik. Rilutek (Riluzole; Covis Pharmaceuticals) is indicated for the treatment of ALS and the mechanism by which riluzole exerts its therapeutic effects in patients with ALS is still unknown. Another approved drug Tiglutik (riluzole), an oral suspension, is the first and only easy-to-swallow thickened riluzole liquid for ALS and is administered twice daily via an oral syringe. On the other hand, Exservan is an oral Riluzole film used to treat ALS. Nuedexta is available as a combination drug containing dextromethorphan hydrobromide and quinidine sulfate indicated for the treatment of pseudobulbar affect. Radicava (Edaravone; Mitsubishi Tanabe Pharma) is another treatment option for the ALS. During clinical trials, it has shown to decrease the decline of the physical functions, however, it is capable of causing adverse effects owing to its constituent sodium bisulfite.

Request for sample @Amyotrophic Lateral Sclerosis Treatment Marketfor rich insights into treatment modalities

Medications are also be given to manage symptoms of ALS, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs also are available to help individuals with pain, depression, sleep disturbances, and constipation. There also exists a variety of tools and mechanical devices such as non-invasive ventilation (NIV) and mechanical ventilation for breathing support to help with ALS such as splints, reach extenders, and grab-bars.

However, the Amyotrophic Lateral Sclerosis therapeutic market lacks a curative approach that can halt or reverse the progression of the disease. Even though Radicava can effectively delay physical disability in ALS patients, however, its high pricing may pose a threat to the overall patient compliance of the drug. Furthermore, the lack of epidemiological data of the disease in the pediatric population hinders the development of novel therapies focused on children below 18 years of age.A poor understanding of the mutations, which form a major cause of the ALS, dims down the ongoing speed of the development of the pipeline therapies. Thus, there is a need for better research opportunities in the domain to facilitate a better understanding of the disease and development of potential novel therapies.

Amyotrophic Lateral Sclerosis Pipeline Therapies

Know more about the top emerging therapies in the ALS market @ Amyotrophic Lateral Sclerosis Drug Pipeline

Amyotrophic Lateral Sclerosis Market Forecast

DelveInsight estimates that approval of novel Amyotrophic Lateral Sclerosis pipeline therapies is expected to give the ALS market size a much-needed boost in the foreseeable future. Although, most of the therapies are going to get commercialized in combination with Riluzole and Radicava. In addition to this, other emerging therapies are under trials while the patient is already following their treatment regimen of Riluzole. Thus, it can be said that the pipeline therapies will be sharing the market share with the available market therapies.

Majority of emerging drugs are focusing on delaying the disease progression, and are not curative. Thus, the ALS market presents immense opportunities for pharmaceutical companies to explore and exploit their ground-breaking therapies and occupy the maximum potential. Here, gene and enzyme replacement therapies, which promise to cure the disease completely, automatically get the upper hand here. Several pharmaceutical companies are investigating novel approaches and joining hands with others to expedite the development of ALS treatment options. Recently, Catalent and BrainStorm entered into an agreement to manufacture NurOwn. Cytokinetics and Astellas entered into the Fast Skeletal Regulatory Activator Agreement, allowing Cytokinetics to exercise exclusive control over the future development and commercialization of reldesemtiv and other FSRA compounds and products. Besides agreements, acquisition spree in the ALS market is quite dominant as well. UCB acquired Ra Pharmaceuticals and got zilucoplan, which is currently in phase III, to its vast portfolio. Similarly, Novus Therapeutics completed the acquisition of Anelixis Therapeutics, which is conducting a phase II clinical trial of AT-1501 for ALS.

Although several clinical trials are ongoing, however, an unsettling thing that might be a snag in the steady growth of the Amyotrophic Lateral Sclerosis market is the quite unpropitious success rate of the clinical trials. The management of ALS is extremely expensive. Expensive drugs like Radicava pose a burden for ALS patients as not everyone can get access to the drug due to its high cost. Thus, the cost-effectiveness of the upcoming therapies is also expected to play a major part in their approval.

Know more about the collaboration and funding ongoing @ Major collaborations in Amyotrophic Lateral Sclerosis Market

Scope of the report

Geography Coverage: The United States, EU5 (Germany, France, Italy, Spain, and the United

Kingdom), Japan.Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).Amyotrophic Lateral Sclerosis Market Segmentation: By Geographies, By Therapies.Key Players Involved: Orphazyme, Biogen/Ionis Pharmaceuticals, MediciNova, AB Sciences, Novus Therapeutics, Seelos Therapeutics, Brainstorm-Cell Therapeutics, Amylyx Pharmaceuticals, Gilead Sciences, PTC Therapeutics, GlaxoSmithKline, Clene Nanomedicine, Alexion Pharmaceuticals, Biohaven Pharmaceuticals, UCB Pharma, and several others.Analysis: Comparative and conjoint analysis of Amyotrophic Lateral Sclerosis Emerging therapies, Attribute AnalysisAmyotrophic Lateral Sclerosis Market trends, pipeline analysis across different stages of development (Phase III and Phase II), and Amyotrophic Lateral Sclerosis Market size by therapies.Tools used: SWOT analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.Case StudiesKOL's ViewsAnalyst's Views

Table of Contents

1

Key Insights

2

Executive Summary of Amyotrophic lateral sclerosis

3

Competitive Intelligence Analysis for Amyotrophic Lateral Sclerosis

4

ALS Market Overview at a Glance

5

ALS - Disease Background and Overview

6

Amyotrophic Lateral Sclerosis Patient Journey

7

Amyotrophic Lateral Sclerosis Epidemiology and Patient Population

8

ALS Treatment Algorithm, Current Treatment, and Medical Practices

9

Amyotrophic Lateral Sclerosis Unmet Needs

10

Key Endpoints of Amyotrophic lateral sclerosis Treatment

11

ALS Marketed Products

12

Amyotrophic Lateral Sclerosis Emerging Therapies

13

ALS Seven Major Market Analysis

14

Attribute analysis

15

Amyotrophic Lateral Sclerosis (7MM) Market Outlook

16

Access and Reimbursement Overview of ALS

17

KOL Views

18

Amyotrophic Lateral Sclerosis Market Drivers

19

ALS Market Barriers

20

Appendix

21

DelveInsight Capabilities

22

Disclaimer

23

About DelveInsight

Related Reports

Amyotrophic Lateral Sclerosis Pipeline Insight

DelveInsight's, "Amyotrophic lateral sclerosis Pipeline Insight, 2020," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Amyotrophic lateral sclerosis pipeline landscape.

Amyotrophic Lateral Sclerosis Epidemiology Forecast

DelveInsight's 'Amyotrophic lateral sclerosis Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Amyotrophic lateral sclerosis (ALS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Multiple System Atrophy Market

DelveInsight's "Multiple System Atrophy (MSA) Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Multiple System Atrophy (MSA), historical and forecasted epidemiology as well as the Multiple System Atrophy (MSA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Multiple Sclerosis Market

DelveInsight's "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Alzheimer's Disease Market

DelveInsight's "Alzheimer's disease Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Alzheimer's disease, historical and forecasted epidemiology as well as the Alzheimer's disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Aneurysmal Subarachnoid Hemorrhage Market

DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Binge Eating Disorders Market

DelveInsight's "Binge (Eating) Disorders - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Binge (Eating) Disorders, historical and forecasted epidemiology as well as the Binge (Eating) Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:

Shruti Thakur[emailprotected]+1(919)321-6187www.delveinsight.com

SOURCE DelveInsight Business Research, LLP

Read more:
Amyotrophic Lateral Sclerosis Market Anticipates Sizeable Growth at a CAGR of 28% during the forecast period (2020-2030) with the US expected to top...